The QualityStocks Daily Monday, January 4th, 2020

Today's Top 3 Investment Newsletters

QualityStocks(OMTK) +325.93%

BUYINS.NET(CHEK) +215.22%

MarketBeat(TURN) +192.26%

The QualityStocks Daily Stock List

Gold X Mining Corp. (GLDXF)

Stock Gumshoe, Mining Journal, Gold Stock Data, ValuetheMarkets, Crush the Street, Global Banking and Finance, Mining Stock Education, TradingView, TMX.com, OTC Markets, Mining News Daily, Resource World, InvestorX, Metals News, InvestorsHub, Global Mining Review, Investing.com, MarketWatch, GlobeNewswire, Baystreet.ca, TMXmoney, Market Screener, Morningstar, Stockhouse, Simply Wall St, YCharts, Seeking Alpha, Financial Content, GuruFocus, Barchart, and TF Metals Report reported beforehand on Gold X Mining Corp. (GLDXF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Gold X Mining Corp. is a junior mining company listed on the OTC Markets’ OTCQX. It is presently moving toward a Feasibility Study (FS) for the Toroparu Project in Guyana, South America with 7.4 million ounces of gold in the Measured and Indicated categories. The Company previously went by the name Sandspring Resources Ltd. It changed its name to Gold X Mining Corp. in November of 2019. Incorporated in 2006, Gold X Mining is headquartered in Centennial, Colorado.

Gold X Mining also holds a 100 percent interest in the Chicharrón Project situated in the Segovia-Remedios mining district, Antioquia, Colombia. Regarding the Toroparu Gold Deposit, it is in the highly prospective Upper Puruni River Region of western Guyana. It contains the largest in-situ gold projects owned by an independent junior mining company in South America.

Gold X Mining’s 100 percent controlled Upper Puruni Concession contains 53,844 hectare (538 km2) of mineral leases positioned in the Cuyuni-Mazaruni Region (Region 7) of Western Guyana. Facilities at Toroparu include a 200-person camp and 2,500-foot all-weather airfield.

A Preliminary Economic Assessment (PEA) study (Preliminary Economic Assessment Report, Toroparu Gold Project, Upper Puruni River Area, Guyana, dated July 18, 2019 completed by SRK Consulting (U.S.), Inc.) defined a 5.02 M-oz Potentially Mineable Gold Resource producing 188,000 ounces of gold per year over a 24-year mine-life.

Currently, Toroparu is accessed overland by way of the 240-km Itiballi-Puruni-Papishao Landing Road, which Gold X Mining rehabilitated in 2003, and is a major corridor for western Guyana and one of its important gold producing areas. Plans include completion of a second access road extending to the north to Buckhall on the Essequibo River.

Gold X has spent over US$150 million on the Toroparu Gold Project to date to classify 7.35 million ounces of Measured and Indicated and 3.15 M-oz of Inferred Gold Resources, develop engineering studies for use in a Feasibility Study (FS), and define several exploration targets around Toroparu.

This past October, Mr. Paul Matysek, Chief Executive Officer, and Mr. Robert Friedland, Chairman of Gold X Mining announced the start of a minimum 12,000 meters of drilling designed to define continuity of grade within recently discovered high grade gold bearing structures and also upgrade and expand the current mineral resource at Gold X’s 100 percent owned Toroparu Gold Project in Western Guyana.

The design of the High Grade Definition Drill Program is to test continuity of grade within clusters of high-grade mineralization at a number of locations that occur in the sub-vertical structures discovered by HPX/Nordmin. These structures host most of the 1,811 gold assays grading more than 3 g/t gold within the historical Toroparu drill database and appear to extend laterally and below the current open-pit resource shells defined by SRK.

Gold X Mining Corp. (GLDXF), closed Monday’s trading session at $2.52, off by 6.6113%, on 58,108 volume. The average volume for the last 3 months is 43,133 and the stock's 52-week low/high is $0.579999983/$3.50600004.

Hemp Technology, Inc. (HPTY)

MicroCapDaily, Wall Street Window, Stockopedia, Equities, OTC Markets, Investors Hangout, Market Screener, Stockwatch, Fintel, Market Wire News, PR Newswire, Seeking Alpha, Barchart, GuruFocus, News Break, docoh, StockInvest.us, Dividend Investor, FX Empire, The Stock Market Watch, Wallet Investor, MarketWatch, Dividend.com, Webull, Financhill, Trade Ideas, Morningstar, Nasdaq, Stockhouse, OTC Dynamics, Business Insider, InvestorsHub, and TipRanks reported earlier on Hemp Technology, Inc. (HPTY), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Hemp Technology, Inc. is a vertically integrated, publicly traded holding company operating in the hemp industry. It operates and intends to further obtain a divers portfolio of subsidiary companies. The Company has a variety of assets, products, and also ancillary offerings in the hemp and related industries. Hemp Technology is based in Louisville, Kentucky. The Company lists on the OTC Markets.

Hemp Technology produces, manufactures, as well as distributes hemp-derived phytocannabinoids globally. The Company has employees/consultants, operations, and subsidiaries in the hemp, and ancillary product industry in Canada, the USA, and Europe. Hemp Technology has comprehensive experience with supply chain networks and distribution frameworks in hemp and related product supply, packaging supply, and accessory supply.

Hemp Technology has a Team with expertise and demonstrated results in start-ups, strategy, product development, revenue generation, and corporate governance. The Company is continually looking for opportunities and strategic acquisitions, which support its business model and that maintain alignment with the industry environment.

Hemp Technology has acquired substantially all of the assets of True Leaf Pet, Inc. (TLP). TLP has greater than 40 products. TLP is a global pet care company. Its emphasis is offering high quality plant-focused wellness products that improve the quality of life for companion animals. Hemp Technology is operating using the True Leaf Pet brand globally, under the Company’s wholly-owned subsidiary of Hemp Tech, Pet Health Technology, Inc.

In December, Hemp Technology announced the appointment of Ms. Dawn Tonkin as Corporate Finance Controller, effective December 14, 2020. Ms. Tonkin has wide-ranging experience with the financial management of a varied collection of industries. These include financial services, construction, regulated industries, real estate, as well as mining support services.

Ms. Tonkin has worked overseas as a finance professional. This included financial administration within the offshore fund industry, the public reporting environment, as team leader for compliance audits, and at the executive level as Director of Finance and Vice President of Finance and Administration.

Hemp Technology, Inc. (HPTY), closed Monday’s trading session at $0.0006, off by 14.2857%, on 3,567,828 volume. The average volume for the last 3 months is 5,329,845 and the stock's 52-week low/high is $0.000099999/$0.006.

Home Bistro, Inc. (HBIS)

Stockrow, Zacks, SmallCapVoice, Stock Day Media, Stockhouse, FoodzHub, Seeking Alpha, Nasdaq, Fintel, Morningstar, Investing.com, Market Screener, MarketWatch, MacroTrends, OTC Markets, Dividend Investor, Stockwatch, Stockopedia, Business Wire, Simply Wall St, InvestorsHub, MarketBeat, Global Banking and Finance, docoh, GlobeNewswire, GuruFocus, and FX Empire reported previously on Home Bistro, Inc. (HBIS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Home Bistro, Inc. is a provider of high quality, direct-to-consumer, ready-made gourmet meals. The Company provides these meals at www.homebistro.com, which includes meals inspired and created by celebrity “Iron Chef” Cat Cora. In addition, it provides restaurant quality meats and seafood by way of its Prime Chop www.primechop.co and Colorado Prime brands. Home Bistro has its head office in N Babylon, New York. The Company’s shares trade on the OTC Markets.

Home Bistro is a premier gourmet online meal delivery service that has been delivering meals since 2014. The Company’s broader growth strategy is to respond to increasing interest in its products and to widen its penetration of the markets it now serves in the United States.

Regarding its Premium Meats, its Prime Chop offers affordable All-American Premium Meats. These include Raw and Cooked offerings. Chop also offers Samplers, such as the Steak Lover's Sampler Assortment. Furthermore, it offers Soups as well as Desserts.

In November 2020, Home Bistro reported that Total Revenue for three month and nine month periods ended September 30, 2020 increased 54 percent and 59 percent, respectively. This is comparison to the same periods in 2019.

In December, Home Bistro announced the phase one launch of its newly redesigned website at www.homebistro.com and the launch of its new marketing campaign. The Company stated that the next phase of additional enhancements to the site will be released periodically over the next few months.

Zalmi Duchman, Home Bistro Chief Executive Officer, said, “Our newly redesigned website had been in the planning stages for some time and with the recent growth in our online orders, the timing of the launch was fortuitous… Home Bistro is positioned to finish 2020 with strong top line growth as order momentum has increased. Additionally, we look forward to accelerating our growth as a result of our new marketing initiative, as we transition into the new year and beyond.”

In addition, last month, Home Bistro announced it was named to Rolling Stone Magazine’s ‘Top Holiday Meal Delivery Service’ list.

Home Bistro, Inc. (HBIS), closed Monday’s trading session at $1.10, up 25.7143%, on 900 volume. The stock's 52-week low/high is $0.75999999/$3.00.

NewAge, Inc. (NBEV)

Market Chameleon, Weedstreet420, Finviz, Insider Tracking, MarketWatch, Stocklight, MacroTrends, Barchart, Stockhouse, Stockopedia, Stocktwits, Investors Observer, Stock of the Week, docoh, Invest Chronicle, Wallet Investor, Investing.com, MarketBeat, ShareInvestor.com, TMXmoney, Morningstar, YCharts, Stocknews, GlobeNewswire, Nasdaq, InvestorsHub, Invest Million, GuruFocus, ETF.com, Seeking Alpha, Market Screener, and Infront Analytics reported previously on NewAge, Inc. (NBEV), and today we report on the Company, here at the QualityStocks Daily Newsletter.

NewAge, Inc. is a healthy and organic products company. It has a network of independent business owners across 75 countries globally. Its commitment is to inspiring and educating consumers to “Live Healthy.” The Company is an omni-channel distribution business with access to traditional retail, e-commerce, direct-to-consumer, as well as medical channels. Established in 2010, NewAge is headquartered in Denver, Colorado.

In late July 2020, NewAge announced that it changed its name to NewAge, Inc. from New Age Beverages Corporation to reflect the strategic priorities of the business and to be representative of the considerable opportunities it sees in the wider consumer products goods space. This change follows the previous announcement to combine with ARIIX and four additional e-commerce and direct selling companies. This creates an international organization with estimated pro forma revenues in excess of $500 million across greater than 75 countries.

In June of 2019, NewAge merged with Brands Within Reach, LLC (BWR) to expand its retail presence and product portfolio. In February of 2020, NewAge launched Noni+CBD shots in Japan, as one of the first major companies to gain approval from the Japanese Ministry of Health. In March of 2020, NewAge launched TeMana Shape, the first product specifically formulated to support intermittent fasting, into a number of key markets globally.

NewAge markets a portfolio of better-for-you products. These include the brands Tahitian Noni, the aforementioned TeMana, Nestea, Volvic, Illy Coffee, Evian, Búcha Live Kombucha, ‘Nhanced, and others. NewAge markets a portfolio of differentiated healthy functional brands in three category platforms. These include Health & Wellness, Healthy Appearance, and Nutritional Performance. The Company operates the websites newage.com, noninewage.com, and a number of other individual brand websites.

In November, NewAge announced it finalized and closed the merger agreement for the acquisition of ARIIX. Details of the final agreement and plan of merger are included in the Company’s Current Report on Form 8-K filed on November 16, 2020. On July 20, 2020, NewAge announced the signing of an agreement to acquire ARIIX and four other e-commerce/direct selling companies. The definitive agreement was amended and restated on September 30, 2020. The expectation is that this combination will create a company with expected annual revenues of greater than $500 million, a blended gross margin of 70 percent, and expected EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of greater than $30 million.

NewAge, Inc. (NBEV), closed Monday’s trading session at $2.65, up 0.760456%, on 1,763,123 volume. The average volume for the last 3 months is 2,255,204 and the stock's 52-week low/high is $0.981000006/$3.49.

Polar Power, Inc. (POLA)

Zacks, Investors Observer, GuruFocus, Renewables Now, StockInvest.us, Invest Million, Stockhouse, MacroTrends, Business Insider, Morningstar, MarketBeat, Finviz, last10k, DBT News, Simply Wall St, Seeking Alpha, Stocktwits, MarketWatch, InvestorsHub, Fintel, GlobeNewswire, Nasdaq, News Daemon, StockNews, Market Screener, Barchart, Dividend Investor, Investing.com, Market Chameleon, Stockopedia, TradingView, News Heater, TMXmoney, and Stock Analysis reported beforehand on Polar Power, Inc. (POLA), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Polar Power, Inc. is a global provider of prime, backup, and solar hybrid power solutions. It designs, manufactures, and sells Direct Current, or DC, power systems, lithium battery powered hybrid solar systems, as well as lithium battery storage systems. These are for applications in the wireless telecommunications tower market and in other markets, including military, electric vehicle charging, cogeneration, distributed power, and uninterruptable power supply. Established in 1979, Polar Power is based in Gardena, California. The Company’s shares trade on the Nasdaq Global Select Market.

Within the telecommunications market, Polar Power’s systems provide reliable and low-cost energy for applications for off-grid and bad-grid applications with critical power needs that cannot be without power in the event of utility grid failure. The Company is one of the technology leaders in providing power and cooling solutions for telecommunications power and cooling, renewable energy, military applications, marine, oil fields, and rapid charging electric vehicles (EVs).

Over the last three decades, Polar Power’s products are well represented in more than 100 countries. The Company’s products are designed, made, and manufactured in California. Polar Power is an industry leader, leading the industry for DC generators, hybrid power systems, and custom power solutions.

Regarding Hybrid Power Systems, Polar Power has its Polar Hybrid solution. The design of it is to support 100 percent network up-time. Polar Hybrid is a hybrid power system for off-grid and unreliable grid cell sites, which cuts diesel-related costs by up to 85 percent.

A two-cabinet modular design, or single shelter all-in-one solution, enables high reliability and ease of installation. Polar Hybrid can work as a fuel-battery hybrid system (diesel, NG or LPG + LiFePO4 or other chemistries). In addition, it can work with any combination of grid or renewable energy sources and diesel generator back-up.

Pertaining to Military applications, Polar Power has been providing DC generators to the US military since 1989. The Company has specialized in custom power systems requiring small quantities with speedy delivery. Polar Power has provided systems operating at the highest elevations to underwater; the warmest and coldest climates; and also from desert sand to marine environments.

Polar Power, Inc. (POLA), closed Monday’s trading session at $4.85, up 1.5707%, on 685,425 volume with 5 trades. The average volume for the last 3 months is 3,379,195 and the stock's 52-week low/high is $0.949999988/$6.63999986.

Radient Technologies, Inc. (RDDTF)

Profit Confidential, Investing.com, Simply Wall St, New Cannabis Ventures, Stockwatch, Barchart, WeedStreet420, Investor Ideas, Green Market Report, StockInvest.us Macroaxis, GlobeNewswire, Dividend.com, Seeking Alpha, Nasdaq, CEO.ca, InvestorX, OTC.Watch, The Dank Investor, Technical420, Stockhouse, Morningstar, GuruFocus, Wallmine, InvestorsHub, Market Screener, Fortune420, Investors Observer, TMX.com, Business Insider, BioSpace, and Wallet Investor reported earlier on Radient Technologies, Inc. (RDDTF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Radient Technologies, Inc. is a manufacturer of high quality cannabinoid-based formulations, ingredients, and products. The Company employs a proprietary extraction and downstream processing platform that recovers up to 99 percent of cannabinoids from the cannabis plant. Radient’s focus is creating innovative products and formulations that fulfill key manufacturing requirements - whether for foods and beverages, beauty products, or pharmaceuticals. Radient Technologies is headquartered in Edmonton, Alberta. The Company lists on the OTC Markets Group’s OTCQX.

Radient Technologies develops specialty products and ingredients that contain a wide array of cannabinoid and terpene profiles. This is while meeting the highest standards of quality and safety. The Company provides its customers and partners with white label extracts, formulations, as well as finished products.

Radient produces novel ingredients, extracts, formulations, and products that have a longer shelf life and improved taste/flavour/aroma profiles. It produces standardized products that can reproducibly ensure exact strength and potency, and medicinal products with a full plant profile - in line with the “entourage effect”.

The Company's platform provides substantially faster extraction rates leading to decreased processing time, increased throughputs, and reduced processing time. Additionally, Radient provides efficient "single stage" extraction leading to increased overall recovery/yield of valuable active compounds (up to 99 percent), and decreased heat degradation of sensitive molecules leading to improved products. Furthermore, the platform provides improved extraction selectivity and purity leading to novel, differentiated products, as well as ease of commercial scalability.

Last month, Radient Technologies announced a licensing agreement with Tunaaaaroom (Tunaaaa) to manufacture and distribute a broad variety of premium cannabis extracts targeting the recreational cannabis consumers in Canada. Based in Edmonton, Alberta, Tunaaaa has spent more than six years developing the genetics for greater than 1000 high-quality cannabis strains containing proprietary terpene profiles.

Via this licensing deal, Radient Technologies will gain access to Tunaaaa's specific genetics. Moreover, it will engage the Tunaaaa breeders as consultants to help boost product development.

Radient Technologies, Inc. (RDDTF), closed Monday’s trading session at $0.0653, up 1.9516%, on 130,977 volume. The average volume for the last 3 months is 88,681 and the stock's 52-week low/high is $0.041999999/$0.312000006.

Transphorm, Inc. (TGAN)

Stock Titan, Zacks, OTC Dynamics, OTC Markets, Nasdaq, Stock Analysis, News Break, MacroTrends, PitchBook, Dividend.com, Fintel, docoh, Stockopedia, Stockwatch, Wallmine, Trade Ideas, Morningstar, AFP.com, The Globe and Mail, MarketBeat, InvestorsHub, Market Screener, Simply Wall St, GuruFocus, MarketWatch, Seeking Alpha, Stockhouse, and Stock Investor reported previously on Transphorm, Inc. (TGAN), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Transphorm, Inc. is a pioneer in and global supplier of high reliability, high performance gallium nitride (GaN) power conversion products. The Company deploys its unique vertically-integrated business approach that leverages the industry’s most experienced GaN engineering team at every development stage: design, fabrication, device and application support. Transphorm is headquartered in Goleta, California and has manufacturing operations in Goleta and Aizu, Japan. The Company lists on the OTC Markets’ OTCQB.

Transphorm has one of the largest Power GaN IP (Intellectual Property) portfolios of more than 1,000 owned or licensed patents. The Company produces the industry’s first JEDEC and AEC-Q101 qualified high voltage GaN semiconductor devices. Its innovations are moving power electronics beyond the limitations of silicon to realize greater than 99 percent efficiency, 40 percent more power density, as well as 20 percent lower system cost.

Pertaining to its GaN Technology, Transphorm’s SuperGaN Gen IV benefits include increased performance. Gen IV provides a flatter and higher efficiency curve with an improved Figure of Merit (RON*QOSS) of approximately 10 percent. In addition, benefits include easier designability, enhanced inrush current capability (di/dt), reduced device cost, and proven robustness/reliability.

In December, Transphorm announced it entered into an expanded, multi-year cooperation and development agreement with its long-term strategic partner, Yaskawa Electric Corporation. As part of the agreement, Yaskawa will make investments in Transphorm totaling $4 million, with the first tranche of $1 million to be provided by mid-December 2020. The agreement is an expansion of the next phase of cooperation initiated in 2017 with Yaskawa’s investment of $15 million in Transphorm. Yaskawa Electric Corporation is the leading manufacturer of low and medium voltage variable frequency drives, servo motors, machine controllers and industrial robots.

Also in December, Transphorm announced the closing of a common stock only private placement of 5,000,000 shares at a price of $3.00 per share. This resulted in gross proceeds to Transphorm of $15.0 million, before deducting placement agent commissions, financial advisor fees, and other offering expenses.

The Company intends to utilize the net proceeds to scale volume shipments of GaN products for the fast charging power adapter, server, communication and gaming power supply markets and converters/inverters for industrial and renewable applications, expanded sampling and qualification in EV automotive applications, growth of its epi wafer business, and also working capital to support general operations.

Transphorm, Inc. (TGAN), closed Monday’s trading session at $4.00, off by 2.439%, on 854 volume. The stock's 52-week low/high is $2.29999995/$50.00.

Silex Systems Limited (SILXY)

Stockaholics, Penny Stock Hub, Speculating Stocks, Proactive Investors, Wallet Investor, OTC Markets, OTC.Watch, Investing.com, and 4-Traders reported beforehand on Silex Systems Limited (SILXY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Silex Systems Limited is a high-technology company based in Australia. It focuses on the delivery of the innovative and disruptive SILEX Laser Enrichment Technology as the next generation technology for the worldwide uranium enrichment industry. The Company invented and initially developed the ‘SILEX’ laser-based uranium enrichment technology in Sydney during the 1990’s. Silex Systems lists on the OTC Markets Group’s OTCQX.

The ‘SILEX’ laser-based uranium enrichment technology was licensed exclusively in 2006 to GE-Hitachi Global Laser Enrichment LLC (GLE). GLE is a business venture presently consisting of GE (51 percent), Hitachi (25 percent) and Cameco (24 percent). Silex and GLE jointly continue to commercialize the technology for potential deployment in the United States. Silex Systems scientists Dr. Michael Goldsworthy and Dr. Horst Struve invented the SILEX technology in the mid 1990’s at Lucas Heights, Sydney.

In essence, the SILEX technology is an inventive laser-based process. It has the potential to economically separate uranium isotopes as well as commercially valuable isotopes of a number of other elements. Its advantages over other uranium enrichment processes include inherently higher efficiency resulting in lower costs. Advantages also include a smaller environmental footprint than centrifuge and diffusion plants. Furthermore, it has greater flexibility in producing advanced fuels for next generation small modular reactors (SMR's). The SILEX technology is also expected to have the lowest capital costs of all enrichment technologies.

Silex subsidiary Translucent, Inc. developed a novel set of semiconductor materials known as ‘crystalline Rare Earth Oxides’ (cREO™). These are for application to the manufacturing of next generation semiconductor devices used in wireless communications, power electronics and other advanced semiconductor industries.

Silex Systems recently provided an update on its recent activities. Silex is working towards finalization of a binding purchase agreement for the restructure of SILEX technology licensee GE-Hitachi Global Laser Enrichment LLC (GLE). This follows the signing of a Term Sheet on February 5, 2019 that provides the key terms for a proposed joint purchase by Silex and Cameco of GE-Hitachi’s (GEH) 76 percent interest in GLE. Subject to obtaining U.S. Government approvals, the proposed restructure of GLE would result in Silex Systems acquiring a 51 percent interest, and Cameco increasing its interest in GLE from 24 percent to 49 percent.

Regarding the Translucent cREO™ technology and IQE, IQE Plc (LON: IQE), who acquired Translucent’s unique cREO™ semiconductor materials technology in March of 2018, disclosed on March 20, 2019 in the commentary to its full year results that positive progress continues to be made in the commercialization of cREO™ for application in many of its key target markets. A perpetual royalty of between 3 percent and 6 percent will be payable to Translucent on the sale of any IQE products globally that use the cREO™ technology, with minimum annual royalties due to start being paid in FY2020 for the first 6 years.

Silex Systems Limited (SILXY), closed Monday’s trading session at $4.00, up 67.294%, on 2,500 volume. The average volume for the last 3 months is 452 and the stock's 52-week low/high is $0.596199989/$4.21000003.

MassRoots, Inc. (MSRT)

Stock News Now, OTCtipReporter, PennyStockScholar, Profitable Trader Authority, SmallCapVoice, Penny Stock 101, CFN Media Group, Wealth Daily, Cannabis Financial Network News, Promotion Stock Secrets, Stock Commander, Damn Good Penny Picks, Penny Picks, OTCJournal, and StockRockandRoll reported earlier on MassRoots, Inc. (MSRT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

MassRoots, Inc. is a leading technology and rewards platform for medical cannabis patients and businesses. Individuals use its application to share their cannabis experiences and stay connected with local dispensaries. MassRoots has affiliations with the top organizations in the cannabis industry. MassRoots lists on the OTC Markets Group’s OTCQB.

MassRoots’ product pipeline includes Dispensary Finder & Menus; Product Pages & Reviews; Sponsored Posts 2.0; and Enhanced Profiles. The majority of the Company’s advertising revenue has come from dispensaries and cannabis-brands in the States of California and Colorado.

Businesses can use MassRoots to advertise their goods and services to cannabis consumers.  MassRoots starts adding in features. These include order ahead, delivery, and the in-app purchase of ancillary products as regulations allow.

In January of 2017, MassRoots acquired DDDigtal, d.b.a. "Whaxy”. This is an online order-ahead and menu management platform. MassRoots has made a strategic investment in High Times Holding Corporation, "High Times", the leading voice of the Cannabis Industry.

MassRoots also acquired Odava, Inc. MassRoots now offers dispensaries a complete set of software to manage their regulatory compliance, streamline their supply chain, and develop successful consumer loyalty programs. Odava is a foremost compliance and point-of-sale (POS) system for the cannabis industry.

Furthermore, MassRoots acquired CannaRegs, Inc. CannaRegs is a top technology platform. It tracks changes in cannabis regulations and taxation at the municipal, state, and federal levels. Moreover, MassRoots created MassRoots Blockchain Technologies, Inc. This is a wholly-owned subsidiary of MassRoots committed to developing blockchain-based solutions for the cannabis industry.

In late December, MassRoots announced that its WeedPass™ rewards system has gained adoption by over 140 dispensary locations since launching in August of 2018. MassRoots is continuing to expand the diversity of rewards offered by WeedPass™ and the markets in which it's available. At present, the Company offers its WeedPass™ rewards program to regulated dispensaries in Denver and Los Angeles. It plans to expand to the San Francisco and Phoenix markets in early 2019. WeedPass™ enables consumers to earn tickets to movies, sporting events, as well as festivals by shopping at participating dispensaries.

MassRoots, Inc. (MSRT), closed Monday’s trading session at $0.0124, up 96.8254%, on 86,519,014 volume. The average volume for the last 3 months is 5,958,517 and the stock's 52-week low/high is $0.001/$0.0085.

Vitality Biopharma, Inc. (VBIO)

Penny Stock Tweets, Zacks, The OTC Reporter, Finance Registrar, MarketWatch, GuruFocus, Stock Beast, SmallCap Network, Stockhouse, and Promotion Stock Secrets reported earlier on Vitality Biopharma, Inc. (VBIO), and today we report on the Company, here at the QualityStocks Daily Newsletter. 

Vitality Biopharma, Inc.’s dedication is to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. Since 2012, the Company has developed a unique capability to produce molecules via glycosylation. This is a form of enzymatic biosynthesis, which was originally developed to improve the taste of stevia. The platform is well suited for the discovery of new pharmaceutical products. OTCQB-listed, Vitality Biopharma has its headquarters in Los Angeles, California.  

  Late in 2015, Vitality successfully modified cannabidiol (CBD), which is not psychoactive. In continuing work, the Company has created a novel class of pharmaceuticals called cannabosides. Cannabosides, upon ingestion, can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. 

Vitality Biopharma can biosynthesize cannabinoid glycosides (cannabosides) via enzyme biosynthesis. The Company is one of only a very few groups in the world who know how to produce and work with the enzymes that perform glycosylation. It has been focused on it because the same enzymes are used to modify the taste of stevia (steviol glycosides).   

Vitality Biopharma has developed a proprietary biosynthesis technology that can modify cannabinoids to create pharmaceutical prodrugs that have no psychoactivity and that can provide targeted disease treatment. The process involves small molecule glycosylation, where sugar molecules are attached to cannabinoids, creating new compounds called cannabinoid glycosides, or cannabosides. 

The Company has introduced its lead cannabinoid drug formulation VITA-100 as a non-psychoactive prodrug of THC. Vitality is centering initial clinical development efforts on VITA-100, a proprietary THC cannabinoid drug formulation. The treatment indications it plans to evaluate in Phase 2 trials include inflammatory bowel disease (IBD), irritable bowel syndrome, and narcotic bowel syndrome (a severe form of opiate-induced abdominal pain). 

Vitality Biopharma announced in April 2018 the pending establishment of a wholly-owned Canadian subsidiary, Vitality Genetics, Ltd. This subsidiary will focus on and enable the performance of a wide assortment of cannabinoid genetics research and development (R&D) programs. 

Vitality Biopharma announced in May the discovery of new antimicrobial activity of cannabinoids and its application for treatment of C. difficile-associated diarrhea and colitis. In experiments executed according to guidance by the Clinical Laboratory and Standards Institute (CLSI), Vitality determined that cannabinoids (including THC) are effective antibiotics for C. diff, VRE, and a variety of additional pathogens. 

Recently, Vitality Biopharma announced that during a recent in vitro safety pharmacological screening study, its lead drug candidate VBX-100 demonstrated no signs of adverse pharmacological effects. This affirms its potential for extensive clinical use as a GI-targeted prodrug of THC. Vitality Biopharma has filed for intellectual property (IP) protection on greater than 100 different glycoside prodrugs. This includes VBX-100. 

Vitality Biopharma, Inc. (VBIO), closed Monday’s trading session at $0.10, up 66.6667%, on 44,840 volume. The average volume for the last 3 months is 27,233 and the stock's 52-week low/high is $0.009999999/$0.50.

HealthLynked Corp. (HLYK)

OTC Markets and InvestorsHub reported on HealthLynked Corp. (HLYK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

HealthLynked Corp. centers on improving healthcare services for patients and physicians. Its technology lessens wait times with online scheduling of appointments and real-time appointments by local providers. Furthermore, the Company’s technology provides easy access to an individual’s and their family’s updated medical records. HealthLynked has its corporate headquarters in Naples, Florida.

The Company concentrates on improving healthcare through connecting patients with their healthcare providers. The HealthLynked Network focuses on the efficient, secure exchange of medical information between patients and their healthcare providers. The cloud-based HealthLynked Network lets patient's medical records move with them. This is so one’s medical records are not fragmented in manifold healthcare systems and/or EHR (Electronic Health Record) systems.

The HealthLynked Healthcare Summary permits patients to maintain a complete medical profile in coordination with physicians. All information is systematically categorized. As a result, physicians have a total overview of patient health without them having to fill unnecessary paperwork.

HealthLynked profile information safeguards that doctors don't prescribe potentially harmful medications in case a patient forgets to mention one or more present medications while talking to their doctor. Moreover, the HealthLynked Healthcare Summary page enables patients to keep their medical records updated. This helps physicians to be more productive and provide valid medical care.

In August, HealthLynked announced the release of its latest software upgrade to the Company’s network, which allows physicians to connect with other physicians across the country. The new service facilitates and encourages several critical interactions among healthcare providers that can substantiallly improve patient care.

This application enables healthcare providers to “lynk” to one another through HealthLynked’s online directory of more than 880,000 healthcare providers in the U.S. Upon being connected, physicians can communicate through online messages or in real time through the Company’s online chat feature. They can also can share files, medical articles and can engage in group discussions with numerous physicians.

Recently, HealthLynked announced the launch of its mobile app for Android™ mobile devices, which connects patients (users/members) with their healthcare providers. Its application permits members to access their HealthLynked profile and medical information while in transit, eliminating redundant paperwork and the need to carry physical medical records and insurance cards to physician office visits.

HealthLynked Corp. (HLYK), closed Monday’s trading session at $0.23675, up 110.071%, on 5,350,989 volume. The average volume for the last 3 months is 608,923 and the stock's 52-week low/high is $0.054999999/$0.25.

U.S. Stem Cell, Inc. (USRM)

InvestorsHub, MarketWatch, TradingView, and Money Morning reported on U.S. Stem Cell, Inc. (USRM), and today we report on the Company, here at the QualityStocks Daily Newsletter.

U.S. Stem Cell, Inc. is a developing business in the regenerative medicine/cellular therapy industry. The Company is a developer of novel autologous cell therapies, and a provider of physician-based stem cell therapies to human and animal patients. U.S. Stem Cell is based in Sunrise, Florida. The Company formerly went by the name Bioheart, Inc. It changed its name to U.S. Stem Cell, Inc. in October of 2015.

The Company has three operating divisions: US Stem Cell Training, Vetbiologics, and US Stem Cell Clinic. U.S. Stem Cell is a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions. Its concentration is on the discovery, development, and commercialization of cell-based therapeutics that prevent, treat, or cure disease through repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function.

U.S. Stem Cell’s business includes the development of proprietary cell therapy products and revenue generating physician and patient based regenerative medicine/cell therapy training services. In addition, the Company’s business includes cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic.

U.S. Stem Cell’s lead product candidate is MyoCell®. This is a muscle stem cell therapy intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack.

MyoCell SDF-1 has received approval from the Food and Drug Administration (FDA) to commence human clinical trials. The intention of MyoCell SDF-1 is to be an improvement to MyoCell.

U.S. Stem Cell has developed a strategic alliance with Advanced Stem Cell Rx (ASC). This includes the development of autologous stem cell treatment centers across the United States. ASC is a U.S. based provider of regenerative medicine programs.

U.S. Stem Cell announced in January 2018 that it reached an important milestone of 10,000 kit sales of its proprietary Adipocell™ product. This is a direct result of its relationships with 287 clinics in the United States and 700-plus physicians worldwide offering the Company’s proprietary stem cell products and services.

Recently, U.S. Stem Cell announced Renewing Our Heroes - a charitable health initiative created to provide first responders and other civil service personnel with access to alternative medical care they would otherwise be unable to obtain - will now offer the Company’s stem cell procedures and protocols to its recipients following injuries and conditions that occur in the line of duty.

Mr. Mike Tomas, U.S. Stem Cell’s President and Chief Executive Officer, said, "Expansion of our stem cell protocol into the line of service for our first responders means we are starting to reach more and more Americans who otherwise would never have access to this incredible regenerative therapy. It is an honor for our organization to know the true heroes of our country can now have access to this standard of care."

U.S. Stem Cell, Inc. (USRM), closed Monday’s trading session at $0.0405, up 231.9672%, on 32,872,320 volume. The average volume for the last 3 months is 1,369,285 and the stock's 52-week low/high is $0.003/$0.0172.

Boston Therapeutics, Inc. (BTHE)

MissionIR,  Tiny Gems, SmallCapVoice, PennyStocks24,   FeedBlitz, Wall Street Mover,  RedChip, TaglichBrothers,  Stock News Now, TopPennyStockMovers, and Information Solutions Group  reported  earlier  on Boston Therapeutics, Inc. (BTHE), and  today we are reporting on  the Company, here at the QualityStocks Daily Newsletter. 

Boston Therapeutics, Inc. is a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases. The Company’s product pipeline  centers  on developing and commercializing therapeutic molecules  that  address diabetes and inflammatory diseases. OTCQB-listed,  Boston Therapeutics is based in Lawrence, Massachusetts.

The Company’s  product pipeline includes BTI-320. This is a  non-systemic, non-toxic,  chewable complex carbohydrate-based compound. The design of it is to lessen post-meal glucose elevation. BTI-320 is a proprietary polysaccharide. 

  BTI-320 works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes, which break down complex carbohydrates into simple sugars, reducing  the availability of glucose for absorption into the bloodstream. 

  Boston Therapeutics  entered a  clinical trial agreement with Joslin Diabetes Center to be the lead clinic  in a Phase II study of BTI-320. In addition,  the Company’s  product pipeline  includes IPOXYN™. This is an injectable anti-necrosis drug. The design of it at first is to treat lower limb ischemia associated with diabetes.  

Boston Therapeutics’  product pipeline also  includes OXYFEX™. This product can serve as the only available oxygen delivery mechanism for animals suffering ischemia or traumatic and surgical blood loss events. OXYFEX™ is  the Company’s  veterinary facsimile to IPOXYN™.

Furthermore, Boston Therapeutics  developed and markets SUGARDOWN®. This is a non-systemic,  complex carbohydrate-based dietary food supplement. The design of SUGARDOWN® is to support healthy blood glucose.

SUGARDOWN®, in its present formulation, is a natural sugar blocker dietary supplement product made completely from a non-digestible sugar molecule, which can help people maintain healthier weight levels. It is the first chewable tablet of its kind. 

In 2015, Boston Therapeutics announced that its affiliate, Advance Pharmaceutical Company Limited (APC), began the  SUGARDOWN®  clinical trial in Hong Kong. Advance is evaluating the effect of  SUGARDOWN®  on Post-Prandial Hyperglycemia in Chinese subjects with Pre-Diabetes.  The lead clinical site is the Department of Medicine, The Chinese University of Hong Kong  (CUHK), Prince of Wales Hospital. 

In April 2017, Boston Therapeutics and  Advance Pharmaceutical announced the fully funded new trial plans to support the safety and efficacy of BTI-320, starting with a randomized, placebo-controlled, double-blinded, multi-center, global study on type 2 diabetic (T2D) patients.

Recently, Boston Therapeutics announced that effective sugar reduction with the investigative BTI-320 formulation necessitates only one tablet. Findings were confirmed by the most recent proof-of-concept study conducted in high-risk Chinese subjects with pre-diabetes. A formulation, in the form of a dietary supplement, is currently available as SUGARDOWN®, SUGARBLOCK and SUGARBALANCE in the Unites States and Asia.

Moreover, in December, Boston Therapeutics announced that it expanded its partnership with Advance Pharmaceutical Company Limited (APC) to distribute in Korea. Following the extension of the licensing and distribution agreement with APC, a registered formulation, marketed as a food supplement under the name SUGARBALANCE is now available in Korea. This significant shipment marks a start to the sales of SUGARBALANCE in the territory.

Boston Therapeutics, Inc. (BTHE), closed Monday’s trading session at $0.0221, up 121.00%, on 2,064,366 volume. The average volume for the last 3 months is 85,839 and the stock's 52-week low/high is $0.005499999/$0.028999999.

Omnitek Engineering Corp. (OMTK)

OTCPicks, Marketbeat.com, FeedBlitz, and Penny Stock Rumble reported earlier on Omnitek Engineering Corp. (OMTK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Omnitek Engineering Corp. develops and sells proprietary diesel-to-natural gas conversion systems and complementary products. This includes new natural gas engines that utilize the Company’s technology. These provide its international customers with unique alternative energy and emissions control solutions that are sustainable and affordable. Omnitek Engineering has its head office in Vista, California.

The Company’s conversion technology provides fleets with a 100 percent dedicated natural gas engine at a fraction of the cost of a new natural gas engine. The strategic alliance provides an assembly-line remanufacturing process providing the benefits of capacity, consistency, as well as quality. Omnitek Engineering’s commitment is to be at the frontier of technology. In addition, its commitment is to develop pioneering solutions that redefine the future of low emissions, energy independence, and transportation.

Omnitek’s products include New Natural Gas Engines, Engine Specific Diesel-to-Natural Gas (DNG) Engine Conversion Kits, and products for Diesel-to-Natural Gas Engine Conversions, Engine Management System (EMS) and Components, EFI for V-Twin Motorcycles and Small Engines, and Hydrogen Internal Combustion Engines. The DNG system has established Omnitek Engineering as a leader in the industry.

The Company has established a strategic alliance with LKQ Corp. to produce "drop-in" natural gas engines at Omnitek Engineering’s facility in Monterrey, Mexico, first for the extensively-used Mercedes OM904 and OM906 engines. LKQ is a top provider of alternative and specialty parts to repair and accessorize automobiles and other vehicles.

Omnitek Engineering announced in July of 2016 that it received global certification for its patented fuel rail technology. This is founded on tests conducted by an independent agency and standards sanctioned by the United Nations Economic Commission for Europe, specifically UN ECE R110.

Omnitek Engineering will participate in a $1.5 million grant study with its partner Olson-Ecologic Testing Laboratories (Fullerton, California). The study is to demonstrate its clean natural gas engine technology for off-road heavy duty construction vehicle applications in the greater Los Angeles, California area.

Omnitek will develop an 18-liter Caterpillar natural gas engine capable of operating on CNG, LNG, or low-carbon intensive renewable biogas (R-CNG) through using its patented diesel-to-natural gas engine conversion technology. Olson-Ecologic Engine Testing Laboratories will serve as project manager. Olson-Ecologic will be responsible for rigorous testing at its facility before demonstrations under real-life conditions.

Omnitek Engineering Corp. (OMTK), closed Monday’s trading session at $0.115, up 325.9259%, on 1,747,633 volume. The average volume for the last 3 months is 47,092 and the stock's 52-week low/high is $0.02105/$0.200000002.

The QualityStocks Company Corner

Loop Insights Inc. (TSX.V: MTRX) (OTCQB: RACMF)

The QualityStocks Daily Newsletter would like to spotlight Loop Insights Inc. (TSX.V: MTRX) (OTCQB: RACMF).

Loop Insights (TSXV: MTRX) (OTCQB: RACMF), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement and automated venue tracing to the brick-and-mortar space, today announced that Internet of Things (“IoT”) partner Telus Corporation (TSX: T) (NYSE: TU) is accelerating its partnership with Loop Insights in 2021. To view the full press release, visit http://ibn.fm/Nkrlz

Loop Insights Inc. (TSX.V: MTRX) (OTCQB: RACMF) is an innovative technology company leveraging Internet of Things (IoT) technologies to deliver contactless solutions, including its venue management platform, personalized engagement services and AI-driven insights.

The company was founded on June 12, 2019, and is headquartered in Vancouver, Canada. Loop is currently offering its solutions to major players in the telecom, sports, casino gaming, hospitality, entertainment and retail industries across Canada, the United States, South America, the UK, Australia, Indonesia and Japan.

Scaled and Fully Managed Services

Loop Insights has integrated both its Fobi and SmarTap devices with its proprietary cloud to provide end-to-end services for the retail, travel, entertainment and hospitality industries.

Loop’s Automated Venue Management Platform

Loop’s venue management platform is a fully managed contactless check-in platform that securely aggregates venue and visitor information in order to generate real-time feedback to both venue hosts and consumers. Loop’s venue management platform can be applied to venue tracing for COVID-19 or used in traditional environments for applications in ticketing, retail and hospitality.

Loop’s COVID-19 Venue Tracing Solution

Loop Insights is committed to leveraging its solutions for COVID-19 management, allowing for easier tracing, testing and data collection.

Loop Insights has adapted its existing technology to create a venue management platform designed specifically for tracing the COVID-19 pandemic. The company’s complete end-to-end COVID-19 management platform provides a means for venues and event hosts to manage attendees and instantly trace and notify potential at-risk visitors.

Loop Insights has partnered with a number of medical testing companies including iSTOC and Empower Clinics to provide rapid testing options wherever its COVID-19 venue management system is deployed.

Loop Insights signed a referral and partnership agreement with Finland’s iSTOC Ltd. in November 2020, providing the company COVID-19 testing and integrated lab capabilities in Europe. The partnership allows Loop to provide FDA and HIPAA-compliant tracing and testing that can be deployed by any health care organization, NGO or government worldwide. “Our partnership with iSTOC positions us as a true global leader regarding complete COVID-19 management solutions,” Loop Insights CEO Rob Anson explained.

Through its partnership with Summit Services Inc., Loop Insights deployed the first-ever COVID-19 venue bubble solution in a live environment at the Gulf Coast Showcase in Fort Myers, Florida, and #VegasBubble in Las Vegas. The venue bubble was deployed to test, trace and notify over 500 NCAA players, coaches and staff that attended the tournament.

Loop’s Personalized Engagement Platform

Loop Insights’ personalized engagement platform leverages the power of the company’s technology to provide retail operators with an automated marketing platform focused on delivering the right marketing to the right customers to optimize retail engagement.

By leveraging the power of the Wallet pass functionality found on all Android and iOS devices, Loop establishes a direct line of communication with consumers, allowing merchants to provide an AI-personalized marketing experience designed to drive spending and encourage brand loyalty through rewards and other promotions.

Like the digital credit cards or boarding passes that use Wallet pass technology, Loop Insights’ engagement platform provides a seamless user experience without the need to download an additional application. Consumers receive automated promotions and discounts that can be personalized based on user data.

Loop’s Real-Time Insights Platform

By aggregating retail information about consumers and their preferences, Loop’s Insights platform takes the guesswork out of decision making for retailers. Loop’s Insights platform aggregates retail performance data, recording 100% of each transaction before delivering insights and analytics regarding macro and micro buying trends, consumer behavior and optimization opportunities.

As part of its Insights offering, Loop provides AI-based forecasting, modeling and inventory management services to retailers with the ability to integrate third-party data services such as foot traffic and weather.

Loop Insights Devices and Technologies

Loop Insights has developed a line of simple, yet powerful technologies designed to transform industries through the power of IoT technologies and artificial intelligence. The company offers fully automated plug-and-play platforms that can seamlessly integrate and enhance clients’ existing operational infrastructure. The company’s devices are designed to work together seamlessly on top of its enterprise-level cloud infrastructure, providing clients in the retail, entertainment and hospitality industries with the ability to easily optimize their operations.

Fobi

Fobi is an IoT device designed to seamlessly integrate into any existing point of sale or customer management infrastructure. It collects 100% of transactional data and then connects this data to other data points, enabling optimization through AI and data-driven insights.

Loop Insights’ cloud-based AI is designed to aggregate an organization’s data, optimizing the information so it is actionable and easy to use. The Fobi device is hardware agnostic and seamlessly connects with existing points of sale or customer relationship management infrastructure, physically or digitally.

By aggregating an organization’s entire dataset, Fobi is able to merge transactional and behavioral data with customer data to create 360-degree customer profiles, enabling highly-personalized, omnichannel marketing strategies across a number of platforms including email, SMS, paper receipts and the company’s proprietary Wallet pass technology. Loop’s data aggregation service is supported by Amazon Web Services, providing clients with the digital infrastructure and security necessary to protect their data.

SmarTap

SmarTap is a Near Field Communication (NFC) device that enables consumers to “tap” to check-in to locations using their smartphone’s NFC compatibility, enabling contactless customer engagement through the use of Wallet pass technology. By leveraging the functionality of the Wallet pass technology found on Android and iOS devices, Loop is able to drive engagement and provide personalized, data-driven insights without the need for an additional application.

Loop’s SmarTap device can connect to the Loop cloud via LTE or Wi-Fi, allowing retailers to securely transfer encrypted data from wherever their businesses operates.

Loop Cloud

The Loop Cloud brings together datapoints from its Fobi and SmarTap devices to create a unified database for the company and its clients. Instead of individual tills and stores generating their own unique datasets, Loop Insights aggregates data together from a number of sources, creating a complete picture of a client’s retail environment.

By hosting this database in the cloud, Loop Insights provides its clients with more accessible and actionable data that can be accessed from anywhere. Additionally, the Loop cloud allows for real-time monitoring, and its API can be directly integrated into existing PoS systems.

When paired with Loop’s Fobi and SmarTap devices, the Loop Cloud allows for businesses to transform their edge-based legacy systems into a unified database that can be accessed from anywhere.

Uklipz

Expected to launch in January 2021, Loop Insights’ latest product offering, Uklipz, is a next-generation platform that enables consumers to create verified video reviews that can be purchased, analyzed and leveraged by brands to drive engagement and sales.

The addition of Uklipz marks an important milestone for the company, because it further strengthens its product portfolio by providing a reliable solution in the massive but problematic consumer review industry, as Anson explained in a November 2020 news release (https://ibn.fm/YpNlR). He added that the company expects this platform to become a very valuable asset and a significant source of revenue in 2021.

Market Outlook

Loop Insights’ integrated technology solutions and its recent advances in providing end-to-end COVID-19 solutions position the company for significant growth opportunities in the expanding IoT market. According to MarketsandMarkets research, the global IoT sector is expected to reach $561 billion by 2022, up from $180.6 billion in 2017. This market growth can be attributed to an increase in cloud platform adoption and a reduction of costs (https://ibn.fm/1BIPB) which Loop is driving through its engagement and insights platforms.

According to Loop Insights’ August 2020 investor presentation, its innovative solutions open the door to multiple opportunities in additional sectors, including but not limited to:

  • Brick and mortar retail – an estimated value of $31,880 billion by 2023 (Mordor Research)
  • Sports and entertainment – an estimated value of $614.1 billion by 2022 (The Business Research Company)
  • Telecom partnerships – an estimated value of $3,435.2 billion by 2022 (The Business Research Company)
  • Casino gaming – an estimated value of $565.4 billion by 2022 (Research and Markets)
  • Cannabis – an estimated value of $66.3 billion by 2025 (Grandview Research Inc.)

Management Team

Rob Anson is the Chief Executive Officer and Chairman of Loop Insights. He has also served, since October 2017, as the Chief Executive Officer and Founder of Fobisuite Technologies Inc., a private British Columbia technology company. In a prior role, Anson was the Founder and Chief Executive Officer of One Team Media, a private Vancouver-based media company with digital and television production assets.

Abbey Abdiye is Chief Financial Officer of Loop Insights. He is a Chartered Professional Accountant (CPA) who has served as Chief Financial Officer for a range of public companies throughout his extensive career. Before obtaining his CPA, he received a Bachelor of Business Administration from Simon Fraser University and completed his Co-Op Education Certificate.

Gavin Lee is the company’s Chief Operating Officer. He has over 20 years of experience with global consumer products, with expertise in building top-performing sales teams, brand management, operational excellence and consumer insights. Lee has a strong business understanding and a background in improving salesforce effectiveness. His experience ranges from small entrepreneurial brands to multi-million-dollar global leaders in a variety of marketing segments.

Casey Matson-DeKay is Chief Technology Officer of Loop Insights. He previously held the same position at Fobisuite Technologies, from January 2017 until January 2018. Matson-DeKay has been a developer and information technology consultant for various enterprises. He has been involved with the core technologies utilized by Loop Insights for nearly a decade.

Loop Insights Inc. (RACMF), closed Monday’s trading session at $1.64, up 2.50%, on 127,317 volume. The stock's 52-week low/high is $0.000000999/$2.33990001.

Recent News

Brain Scientific Inc. (OTCQB: BRSF)

The QualityStocks Daily Newsletter would like to spotlight Brain Scientific Inc. (OTCQB: BRSF).

Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company with two FDA-cleared products, provides next-gen solutions to the neurology market. Neurological care that reduces the opportunity of cross-contamination is critically needed in the effort to combat COVID-19.

Brain Scientific Inc. (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. With a mission of modernizing brain diagnostics by employing cutting edge technologies to bridge the widening gap in access to quality care, the company offers two FDA-cleared products that provide next-generation solutions to the neurology market.

The company’s proprietary, clinical-grade neurological devices are supported by its intellectual property portfolio featuring patents in the United States, China and Europe.

Brain Scientific’s first commercialized devices, NeuroCap(TM) and NeuroEEG(TM), are designed to disrupt the current electroencephalogram (EEG) market by offering cost-effective and disposable substitutes to existing solutions, allowing medical professionals to collect diagnostic information quickly.

The company’s goal is to improve diagnostics by leveraging artificial intelligence and machine learning processes to analyze a database of brain readings as a method of detecting seizures and dementia. The company is also working to improve patients’ access to neurological care.

Headquartered in New York, Brain Scientific and its predecessor (and now wholly owned subsidiary, MemoryMD Inc.) was founded in 2015 and went public in 2018.

Brain Scientific’s first phase of development, from 2018 to 2019, saw the inception of portable, clinical-grade, easy-to-use neurological devices. The second phase, currently ongoing, aims to create cloud-based, secure infrastructure to transmit patient data between patients and their neurologists. The company’s third phase of development is scheduled for 2021-2022 and is expected to focus on the use of AI-assisted diagnostic analysis to increase the efficiency, consistency and accuracy of neurology specialists.

NeuroCap(TM) – Disposable EEG Headset

The NeuroCap is a disposable pre-gelled EEG headset featuring 22 electrodes and 19 active EEG channels, all adhering to the international 10-20 system. The NeuroCap was FDA-cleared in 2018. The headset can be used for recording EEGs in virtually any setting, including urban and rural emergency departments, neurology clinics, urgent care clinics, ICUs, nursing homes, assisted living facilities and remote clinical research labs.

Through a universal cable adapter, the NeuroCap is compatible with other EEG amplifiers. The cap also works in parallel with Brain Scientific’s NeuroEEG amplifier, initiating EEG studies in less than five minutes.

The company is currently seeking FDA approval for additional features for the NeuroCap, as the device has the potential to fill a gap in EEG testing availabilities during the current coronavirus pandemic: in October 2020, Brain Scientific filed an Emergency Use Authorization (EUA) application. The EUA is required for the rapid distribution of the NeuroCap device to emergency departments, intensive care units and other treatment centers to administer prescriptive EEGs safely on critically ill patients or those suspected of being diagnosed with COVID-19.

With more than 80 percent of hospitalized patients infected with COVID-19 displaying neurological symptoms, the NeuroCap could prove to be a valuable device by offering fast testing with limited contact between technicians and patients.

NeuroEEG(TM) – Miniature and Portable Wireless EEG Amplifier

The NeuroEEG is a compact, portable and affordable wireless EEG amplifier intended for prescription use. The 16-channel, FDA-cleared, clinical-grade device acquires, records, transmits and displays electrical brain activity for patients of all ages.

Both the NeuroCap and NeuroEEG are delivered by MemoryMD Inc., a wholly owned subsidiary of Brain Scientific.

Products in Active Development

Currently, Brain Scientific and MemoryMD are working on leveraging their existing products and drawing from ongoing research to develop and commercialize the next generation of solutions for the brain diagnostics market. The devices under development are being designed to address the following issues:

Routine EEG

  • NeuroCap-8 is an 8-channel EEG cap. The reduced number of electrodes is vital in emergency room situations, where the time it takes to set up the EEG is critical.

Pediatric EEG

  • NeuroCap Pediatric is positioned to become the first disposable and pre-gelled headset available for the pediatric market.

Long-Term Monitoring

  • NeuroCap LTM for adult and pediatric patients is a disposable cap designed to monitor rhythmic and periodic patterns for up to 72 hours, providing essential diagnostic capabilities.
  • NeuroEEG 24 Channel Amplifier is a portable and wireless amplifier with over 24 hours of battery life.

Artificial Intelligence

  • Brain E-Tattoo is a minimally invasive four-channel EEG electrode designed for long-term monitoring.
  • An AI database of brain biomarkers collects data on both normal and abnormal brain data to detect neurological diseases. The goal is for machine learning algorithms to enhance understanding of brain-behavior related to epilepsy, memory dementia and pre-Alzheimer’s diagnostics.

Telemedicine

Brain Scientific is expanding the vision for telemedicine in neurology. The company aims to address the current acute neurologist shortfall (20 states have less than 10 neurologists per 10,000 patients) through the use of teleneurology.

 

Partnership with Marketing Brainology

Brain Scientific has a longstanding partnership with Marketing Brainology, a neuromarketing firm using neuroscience approaches to understand consumer behavior. In 2019, Marketing Brainology conducted a study using NeuroCap and NeuroEEG to determine the most effective Super Bowl commercials.

“Thanks to Brain Scientific’s NeuroCap and NeuroEEG, we are able to better understand the art and science of the human decision-making process,” Michelle Adams, Ph.D, Founder of Marketing Brainology, stated in a news release.

In April 2020, Marketing Brainology again conducted a study leveraging Brain Scientific’s disposable EEG cap to determine how brains were reacting to COVID-19 messaging. Subjects were presented with multiple media impressions, and Marketing Brainology analyzed their responsive biomarkers. The results identified the most effective messaging for engaging with an audience during a crisis.

Market Outlook

The current global market for EEG devices is estimated at $956.1 million. It is expected to rise with a CAGR of 8.7% from 2019 to 2026, reaching $1.6 billion in value by 2026, according to Grandview Research.

In total, there are approximately 6,150 hospitals in the U.S., according to the American Hospital Association. Critically, though, just 254 of those hospitals are certified Level 4 Epilepsy centers with 24/7 EEG coverage. Since very few non-Level 4 centers have extensive EEG tech coverage, this creates a significant opportunity for Brain Scientific to bridge the gap by providing over 5,900 hospitals with lower cost amplifiers and disposable EEG caps.

The company also see opportunities to work with other businesses, such as EEG manufacturers hoping to package Brain Scientific’s solutions with their products, which could greatly expand Brain Scientific’s addressable target market.

Management Team

Dr. Baruch “Boris” Goldstein, Ph.D., is co-founder and Chairman of Brain Scientific. He is a seasoned executive with a proven talent for aligning global business strategies with established and emerging management teams. Goldstein’s growth-focused leadership style has helped him raise over $750 million in venture capital for the development of innovative companies and startups in diverse industries, including financial services, biomedicine, alternate energy and new materials, as well as groundbreaking work in artificial intelligence. His recent achievements include important advancements in neurology and unlocking the potential of AI correlations and machine learning applied to life sciences and medical research. He built a suite of first-to-market companies as a technology-oriented leader, including Ryah Medtech, Brain Scientific, GrapheneCA, E-Forex and Intelligent Video Systems. He also co-founded BrainRX, a company specializing in pre-Alzheimer’s diagnostics.

Dr. Nikolay Kukekov, Ph.D., is a Director of Brain Scientific and a partner at HRA Capital. Before joining HRA Capital, Kukekov was Managing Director of Healthcare Investment Banking at Summer Street Research. His scientific background includes a bachelor’s degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder. He earned his Ph.D. in neuroscience from Columbia University – College of Physicians and Surgeons in New York.

Stuart Bernstein is the company’s Vice President of Marketing. He was recently named to the role after spending the first part of his professional career in senior technical management roles with Fortune 500 companies such as NCR (NYSE: NCR), IBM (NYSE: IBM) and Control Data Corp. He was the CEO of BioSignal, an EEG medical device company. He is also a co-founder of several software engineering and telemedicine firms. One of them, Brain Saving Technology, is now Specialist on Call (SOC Telemed) – a leading telemedicine company that powers over 850 facilities for teleneurology, telepsychiatry and critical care telemedicine with over 200 physicians.

Brain Scientific Inc. (OTCQB: BRSF), closed Monday’s trading session at $0.992, up 10.2222%, on 2,000 volume. The average volume for the last 3 months is 3,610 and the stock's 52-week low/high is $0.100000001/$3.00999999.

Recent News

Josemaria Resources Inc. (TSX: JOSE) (OTC: JOSMF)

The QualityStocks Daily Newsletter would like to spotlight Josemaria Resources Inc. (TSX: JOSE) (OTC: JOSMF).

Josemaria Resources Inc. (TSX: JOSE) (OTCQB: JOSMF) was featured today in a publication from MiningNewsWire, examining how University of Colorado Boulder and Carnegie Institution for Science researchers are suggesting that a new system of classifying minerals be implemented. The evolutionary system will not only be inclusive of historical data but also display changes in distribution and diversity of minerals for more than 4 billion years of the history of earth. Also today, the company was featured in a publication from InvestorWire, examining how JOSMF on Thursday announced that, in accordance with the Swedish Financial Instruments Trading Act, as a result of the issuance of common shares pursuant to the terms of previously announced credit facilities, the number of issued and outstanding shares of the company has increased to 301,842,809 common shares with voting rights as of Dec. 31, 2020. To view the full press release, visit http://ibn.fm/3yYUn

Josemaria Resources Inc. (TSX: JOSE) (OTC: JOSMF) is a Canadian natural resources company based in Vancouver, British Columbia. The company’s current focus is on advancing the development of its wholly owned Josemaria copper-gold mining project.

Josemaria Resources is part of The Lundin Group of companies, a conglomerate of 13 business entities operating in the mining, oil and gas and renewables sectors all around the world.

The Josemaria Copper-Gold Project

The company’s flagship Josemaria Copper-Gold Project is located in the San Juan Province of Argentina – a well-known mining hub supporting a wide variety of mining service companies. The Lundin Group has been active in Argentina for approximately 30 years. Committed to advancing the project, Josemaria Resources has already begun the bridging phase, with basic and detailed engineering planning expected to commence in early 2021.

The company recently announced the results of a feasibility study at the Josemaria Project. The study, prepared by a team of engineering and consulting providers including Fluor Canada Ltd., SRK Consulting (Canada) Inc. and Knight Piésold Ltd., highlights a robust, low-risk project with rapid payback expected via an open pit operation with forecast capacity to feed a conventional process plant at a rate of 152,000 tonnes a day over a 19-year mine life.

According to the feasibility study, the project is expected to yield an average annual production of 136,000 tonnes of copper, 231,000 ounces of gold and 1,164,000 ounces of silver. Other highlights of the study include:

  • The optimized mining production plan provides average grades in the first three years of production that are notably better than the life-of-mine average. This supports a forecast 3.8-year payback period from the start of production.
  • The project’s total initial cost, including engineering, procurement, construction, management, on- and off-site infrastructure, contingency and pre-construction engineering work, amounts to roughly $3.09 billion.
  • The location provides readily available access to essential resources, including water, grid power, transportation and logistics infrastructure within San Juan Province.
  • An Environmental and Social Impact Assessment (ESIA) of the project is already underway and is expected to be submitted to relevant authority agencies for review during Q1 2021.

The Josemaria Copper-Gold Project has been designed to incorporate the latest technology. Per the feasibility study, the project will include the use of autonomous trucks and production drill fleets, with the option of incorporating green energy, indicating the company’s commitment to minimizing and mitigating the adverse effects of mining on the environment.

To this end, the company intends to leverage suitable planning, impact assessment and monitoring tools while also incorporating water and energy efficiency systems and ecosystem conservation services in the design and implementation of its operations.

Josemaria Resources President and CEO Adam Lundin welcomed the results of the study as confirming that this is one of the very few readily developable copper-gold projects in the world and forecasting an attractive economic outcome for the asset, comparable with other copper-gold projects in development.

“We believe that Josemaria is perfectly positioned to commence production by mid-decade, meeting rising copper demand from a rapidly electrifying global economy. I believe the study results will allow us to unlock various financing opportunities as we move toward construction,” Lundin said in a news release.

Market Outlook

The global smart mining market was estimated at $6.8 billion in 2019. It is forecast to reach $20.31 billion by 2025. The significant increase is expected to be driven by technological advancements within the sector.

Global demand for copper is also growing steadily, due to the metal’s versatility and multiple uses for industrial, domestic and high-technology indications. The global copper market is expected to reach $222.1 billion by the end of 2026.

Management Team

Adam Lundin is the President, CEO and Director of Josemaria Resources. He has several years of experience in managing capital markets and public companies across the natural resources sector. His background includes oil, gas, mining technology, investment advising, international finances and executive management. Lundin began his career working for several of the Lundin Group mining companies. He is currently engaged in multiple roles, as he is also the Chairman for Filo Mining Corp. and Africa Energy Corp. and a Director of NGEx Minerals Ltd. and the Lundin Foundation.

Ian Gibbs serves as CFO of Josemaria Resources. He is a Canadian Chartered Accountant and a graduate of the University of Calgary, holding a Bachelor of Commerce degree. Gibbs has held many prominent positions within the Lundin Group of companies over the last 15 years, most recently as the CFO of Africa Oil Corp.

Arndt Brettschneider is the company’s Vice President of Projects. He has over 23 years of international mining, consulting and project development experience. Before joining Josemaria Resources, he was Vice President of the mining consulting businesses of two globally recognized engineering companies. Brettschneider obtained a Bachelor of Science with Honors from the University of Queensland in Brisbane, Australia. He received his MBA from Queen’s University in Ontario, Canada.

Bob Carmichael is the company’s Vice President of Exploration. He joined Josemaria Resources from Lundin Mining Corporation’s UK office. In his UK role, he was the General Manager of Resource Exploration. Carmichael is a registered Professional Engineer in the Canadian province of British Columbia. He obtained a Bachelor of Applied Science from the University of British Columbia. His dual role includes serving as Vice President of Exploration for Filo Mining Corp. and NGEx Minerals Ltd.

Alfredo Vitaller is Josemaria Resources’ General Manager in Argentina. He has been involved in the mining industry since 1993. He graduated as a Licentiate in Geological Sciences from Buenos Aires University and has an M.Sc. from Mackay School of Mines at the University of Reno. Vitaller has worked with the Lundin Group since 1993 and was a part of the exploration teams for Filo, Helados and Josemaria.

Notable Directors

Ashley Heppenstall, chairman of the Josemaria Resources board of directors, has over 30 years of experience in the oil and gas and resources sectors. From 2002 to 2015, Heppenstall served as the President, CEO and Finance Director of Lundin Petroleum AB, an oil and gas exploration and production company with core assets in Norway and Southeast Asia. He is credited with building Lundin Petroleum into the largest independent oil firm in the world today, leveraging a single equity raise of $50 million to guide Lundin in the design and implementation of a strategy that’s led it to a current market cap of roughly $6 billion.

Ron Hochstein has worked for the Lundin family directly as a consultant for over 20 years and is currently the President and CEO of Lundin Gold, a gold-producing business whose key asset is the Fruta del Norte gold deposit in Ecuador. Hochstein led construction efforts on the first mine in Ecuador, which went into production in 2019 and was completed on time and on budget.

Paul Conibear has been with The Lundin Group for over two decades, including serving as the CEO and Director of Lundin Mining from 2011 through 2018. Lundin Mining’s current market cap is estimated at $3.5 billion. In total, Conibear has more than 35 years of experience in progressively more responsible positions in the resource sector ranging through management of all phases of mine investment, including exploration, economic assessments, construction, operations and closure.

Josemaria Resources Inc. (TSX: JOSE), closed Monday’s trading session at $0.79, up 2.60%, on 197,600 volume. The average volume for the last 3 months is 145,740 and the stock's 52-week low/high is $0.31/$0.91.

Recent News

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF)

The QualityStocks Daily Newsletter would like to spotlight GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF).

Historically, gold played the role of a safe haven asset during economic decline or increased volatility due to heightened uncertainty. The pandemic has been no different as the precious metal hit its all-time high in early August, surpassing $2,075 per ounce. With the expectation that the price of the precious metal will stay strong in 2021, GoldHaven Resources (CSE: GOH) (OTCQB: GHVNF) looks to be well positioned in the space. As a junior mining company focused on identifying and capitalizing on precious metal projects in mineral-rich districts within stable political jurisdictions, GOH may well be able to leverage the robust momentum of the gold market. Also today, the company was featured in a publication from MiningNewsWire, examining how GHVNF today announced the appointment of Jack Pritting to the company’s advisory board for its Chilean operations. Pritting has extensive experience spanning 40 years in mineral exploration and resides in Santiago, Chile. “Jack’s experience is invaluable to GoldHaven, particularly given his involvement in the exploration of Kinross’s La Coipa mine,” said Daniel Schieber, GoldHaven’s CEO. “Jack was instrumental at La Coipa and led Kinross’s exploration activities in the Andean region from Colombia to southern Argentina.” To view the full press release, visit https://ibn.fm/ixw2M

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (formerly Altum Resources Corp.), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, recently announced its entry into agreements to acquire seven advanced gold projects in the Maricunga Gold Belt of Chile that hosts over 100 million ounces of gold within the last 10 years.

Chilean Gold Properties Being Acquired

On April 17, 2020, GoldHaven Resources entered into an agreement to purchase a 100% interest in two gold projects located in the Maricunga Gold Belt of Northern Chile. The first property, Rio Loa, is located 25 kilometers south of Gold Fields Ltd.’s Salares Norte, where, this year, a five-million-ounce discovery was made. The second property, Coya, is located only 10 kilometers east of the Kinross La Coipa open pit mine, which has produced over 7.5 million ounces of gold to date.

Rio Loa Project

Initial geophysical studies of the Rio Loa site have exposed highly anomalous ardennite and lead values, a key characteristic of gold mineralization within silicified resistive bodies. The studies have also produced initial findings which are similar to those seen at contiguous mines, such as Salares Norte (operated by Gold Fields), which has over five million ounces in estimated gold deposits.

The potential economics for the site look particularly promising when taking the unit costs at the neighboring Salares Norte mine into account. Gold Fields has estimated that its production AISC (all-in sustainable costs) will approximate $552 per ounce and have forecast a 2.3-year payback period for its initial investment, assuming a $1,300 per ounce gold price.

Coya Project

The Coya site is located within close proximity to one of the richest and largest epithermal gold and silver districts in Chile and is in close proximity to active mining sites, specifically the La Coipa mine owned by Kinross. A study carried out in 2017-2018 on the Coya site of 796 rock chip samples found favorable gold and silver values, in some cases ranking as high as 764 grams/tonne of gold and 719 grams/tonne of silver – values which are near certain indicators of potential gold and silver deposits. The La Coipa mine (Kinross) has produced over 6.9 million ounces of gold to date.

On August 11, 2020, GoldHaven Resources acquired five potential gold projects in the Maricunga Gold Belt of Northern Chile. The Maricunga hosts discoveries within the last 10 years of over 100 million ounces of gold and over 450 million ounces of silver. These newly acquired properties are in close proximity to seven other mines, which possess an estimated aggregate of 81 million ounces of gold in total reserves.

GoldHaven’s five new projects cover a total area of approximately 22,600 hectares, or 226 square kilometers, located in the northern portion of the Maricunga Belt in proximity to the 5 million-ounce gold equivalent Salares Norte project owned by Gold Fields. Gold Fields announced in April 2020 its intention to proceed with the development of Salares Norte at a cost of $860 million, with a $138 million expenditure budgeted for 2020.

The Maricunga Belt extends approximately 150 kilometers north-south and 30 kilometers east-west, straddling the border between Chile and Argentina. This region hosts known mineral resources of more than 100 million ounces of gold, 450 million ounces of silver and 1.3 billion pounds of copper.

The Maricunga project’s opportunity came about as a result of a $150 million initiative launched by the Chilean Economic Development Agency (“CORFO”), with the objective of encouraging exploration and mining prosperity in Chile and strengthening Chile’s position as a world leader in the sector.

As part of CORFO’s program, a total of $15.3 million was given to private equity fund IMT Exploration to evaluate 403 projects, beginning in 2011. This led to a generative program carried out from 2016 to 2019, resulting in 126 potential epithermal targets from which 57 field evaluations were made. Due diligence work followed on 19 of these. Work programs were then conducted, including geological mapping, rock and soil sampling and TerraSpec (PIMA) analyses on geochemical grids for alteration mapping, and, as a result, the five high-priority Maricunga projects were identified. No drilling has been carried out on any of the Maricunga projects.

Securing Financing for Upcoming Operations

In conjunction with its announcement regarding its acquisition of five Chilean mining interests, GoldHaven Resources also detailed plans for a non-brokered private placement of 11.5 million units at a price of $0.35 per unit, for gross proceeds of $4,025,000. Each unit will consist of one share of the company and one warrant, the latter of which can be exercised to acquire an additional share of the company for a period of 18 months from the date of issuance at a price of $0.50 per share. Net proceeds from the offering are intended to be used to fund general expenses, as well as exploration and drilling of its mineral properties.

Gold Prices Hit Record High in 2020

Gold prices have been on a remarkable run in 2020, breaking above $2,000 per ounce for the first time on record. Having begun the year at $1,515 per ounce, the precious metal has seen a huge surge on the back of widespread economic uncertainty stemming from governments’ worldwide propensity to expand the money supply, from the reduction of the value of the U.S. dollar as expressed by the decrease in the U.S. dollar index, and from the very real economic effects of the COVID-19 pandemic.

Global central banks have carried out 144 interest rate cuts thus far in 2020, reducing rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures has prompted a number of investment banks to boost their near-term outlooks for gold prices, with Bank of America raising its 18-month gold price target to $3,000 per ounce (http://nnw.fm/PQJtc).

Leadership Team

David Smith, President, CEO and Director, has been immersed in the mining industry for the last eight years, working in corporate development and finance. Prior to GoldHaven Resources, Smith cofounded a multifaceted real estate development and sales company, which has now been in operation for over 35 years. He also cofounded two successful environment-focused companies listed on the Toronto Stock Exchange. Both companies were sold independently and returned a significant profit for shareholders.

Darryl Jones, Chief Financial Officer, is a finance executive and CPA with over 30 years of public company and project buildout experience. Most recently, Jones served as the CFO of Lupaka Gold Corp., retiring in June 2018. Prior to that, Jones serves as CFO of Corriente Resources, which was sold to CRCC-Tongguan in May 2010 for C$680 million.

Patrick Burns, VP Exploration and Director, is a Canadian geologist with over 40 years of experience throughout the Caribbean and Central and South America. He played a direct role in the discovery of the Escondida porphyry copper deposit in Chile and has been involved in publicly traded mining companies, predominantly in Chile, for 35 years.

Marla Ritchie, Corporate Secretary, brings over 25 years of experience in public markets to the GoldHaven team. Throughout this time, she has worked as an administrator and corporate secretary specializing in resource-based exploration companies. Currently, Ritchie is the corporate secretary for several companies, including International Tower Hill Mines Ltd. and Trevali Mining Corp.

Gordon Ellis, Director; has over 50 years’ experience in mining and resource development. A professional engineer and entrepreneur, he has held multiple senior management and director roles with public mining companies, as well as a multi-billion-dollar ETF fund. Ellis holds an MBA in international finance and a Chartered Directors designation.

Scott Dunbar, Director is a professor and head of multiple departments at the University of British Columbia, including mineral extraction and mining innovation, as well as mining engineering. He has been involved in projects around the world in regard to mining exploration, geotechnical engineering and mine design. Dunbar received his PhD in geophysics and civil engineering from Stanford University.

GoldHaven Resources Corp. (OTCQB: GHVNF), closed Monday’s trading session at $0.526105, up 3.6252%, on 89,021 volume. The stock's 52-week low/high is $0.109999999/$0.800000011.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global (OTCQB: SHRG), a diversified holding company specializing in the health and wellness direct-selling industry, has announced two new board members. The new members — Frank D. Heuszel and Sassuan (Sam) Lee — will serve as directors and are Document Security Systems Inc. (“DSS”) board members (https://ibn.fm/TG7h2). DSS owns 37% of the outstanding shares of Sharing Services.

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed Monday’s trading session at $0.24, up 4.3025%, on 118,324 volume. The average volume for the last 3 months is 115,016 and the stock's 52-week low/high is $0.0215/$0.730000019.

Recent News

CannAssist International Corp. (OTCQB: CNSC)

The QualityStocks Daily Newsletter would like to spotlight CannAssist International Corp. (OTCQB: CNSC).

CannAssist International Corp. (OTCQB: CNSC) was featured today in the 420 with CNW by CannabisNewsWire. The year 2020 will undoubtedly go down as one of the most challenging years legal cannabis cultivators have seen in recent times. A worldwide pandemic that claimed more than 1.5 million lives and brought the global economy to its knees coupled with wildfires and early freezes made 2020 a tough year for plenty of growers. With the nascent cannabis space already dealing with issues such as lack of access to banking services and a constantly changing regulatory environment, the landscape was already challenging for legal growers.

CannAssist International Corp. (OTCQB: CNSC), owner of Xceptor Labs, is a biotechnological pharmaceutical and wellness company marketing the Xceptol consumer brand.

CannAssist, a Delaware corporation, was established in May 2017 and is headquartered in San Diego County, California.

2018 Farm Bill and CBD Market Size

Signed into law in December 2018, the Agriculture Improvement Act of 2018 (2018 Farm Bill) removed hemp from its classification as a Schedule I drug under the Controlled Substances Act of 1970.

There are over 100 known cannabinoids within the hemp plant. The two most commonly utilized cannabinoids are THC (tetrahydrocannabinol) and CBD (cannabidiol). Cannabinoids have been shown to affect the endocannabinoid system within the human body, which is why CBD has demonstrated effectiveness as a therapeutic option when delivered through the right absorption avenues.

The 2018 Farm Bill is expected to have a sustained impact on the growth of the cannabidiol market and related sectors. In 2018, the global cannabidiol market was valued at $4.6 billion, and it’s expected to increase almost sixfold by 2025, reaching $23.6 billion (https://ibn.fm/PL6PO).

This growth is expected to provide multiple opportunities to CannAssist and its high-quality, high-performance brands, including products currently under development. Based on current revenue from licensing agreements, retail sales and the Xceptol brand’s international distribution, the company expects to reach first-year sales of $5 million. With additional products in the pipeline and an unwavering commitment to quality and effectiveness, the company expects to see steady sales growth in the years ahead.

Xceptor Labs

Xceptor Labs is an R&D and raw material manufacturing company that partners with TakaUSA, in Coppell, Texas, for contract manufacturing and production services.

CiBiDinol Technology

Xceptor Labs’ technology, CiBiDinol, is formulated using a proprietary process developed by CannAssist Founder Mark Palumbo. It is specifically designed to address many critical issues with oil-soluble CBD molecules, including delivery, bioavailability and short shelf-life. This technology provides the basis for Xceptor Labs and Xceptol consumer products.

CiBiDinol is believed to provide CBD in a format that is more in line with the body’s natural bioactivity. The company’s proprietary processes are used to combine CBD molecules with penetration enhancing cyclodextrin, effectively modifying the CBD molecule’s surface and rendering it water dispersible. This technology enhances absorption through the skin and gut.

The company believes that CBD products created using its CiBiDinol technology offer more predictable potency and enable reduced dosage requirements. This technology clears the way for a wide variety of products, including many oil-soluble active ingredients and highly effective consumer product applications.

Independent Testing

Third-party testing has confirmed that products made with CiBiDinol demonstrate a 400 percent increase in skin penetration as compared to regular CBD in oil carriers alone, as well as a 300 percent higher absorption rate in the gut. The company believes that the results indicate that the amount of CBD needed to achieve targeted endpoints can be significantly lower, resulting in lower costs for manufacturers and consumers with little to no side effects.

“Oversight of manufacturing and third-party testing of this ingredient produced consumer products designed to provide clinicians and consumers safe, effective, and affordable treatment options to address their health and wellness concerns,” Palumbo said in a news release.

CiBiDinol is currently being evaluated for safety by the National Science Foundation for Global Recognition and has been submitted to the FDA’s bulk drug substance program. The company is developing a commerce pathway in each state’s pharmaceutical distribution network through the National Board of Pharmacies. The company aims to capture increasing market share through product extensions and advancements by seeking critical third-party analysis and physician feedback regarding its proprietary technology’s attributes. Xceptor Labs intends to offer licensing arrangements for brand-consumer companies.

Xceptol Products

CiBiDinol technology is the foundation for Xceptor Labs and the Xceptol line of products, including topical creams, capsules, tinctures and pet drops. The Xceptol line began launching its products in September 2020, and it currently has five National Drug Code topical pain creams utilizing ingredients registered with the FDA.

Xceptol products will be sold online, through Range Me, as well as through national and international retail and pharmaceutical distributors. Marketing for Xceptol products is planned through multiple social media campaigns including using celebrities and former athletes associated with Freedman Sports Promotional Relations.

Xceptol is establishing sales channels in North America, Central America, South America, South Africa, the EU, the UK and the Philippines.

Management Team

Mark Palumbo, CEO and Founder, is an entrepreneur, scientist and executive with over 30 years in the health care, laboratory and manufacturing industries. His entrepreneurial endeavors include a successful personal care industry distribution company, a currently owned and operated tissue culture laboratory and Xceptor Labs, now part of CannAssist International.

Marla Palumbo, President, is a health care professional and registered nurse with over 30 years of experience in the industry. She handles sales, patient advocacy, patient care and general management. Marla Palumbo has effectively developed and grown a personal care distribution company with significant year over year increases in sales. Her management and organization skills were instrumental in the early development of Xceptor Labs, leading to its CannAssist International public company status.

Dr. Rahul Dixit, MD, Medical Director, is a doctor of gastroenterology at Providence St. John’s Medical Center in Santa Monica, California. He was part of a double fellowship with the University of Miami in Gastroenterology and Hepatology/Liver Transplant at Johns Hopkins Hospital. He has over 20 years of experience with cannabis and hemp-related products.

Takako McGowan, Managing Director, Founding Member and Owner of TakaUSA, brings 40 years of experience in manufacturing and consumer product research & development to the CannAssist team.

Camron Elizabeth, Managing Director-Sales and Marketing, is an entrepreneur and leader who has brought immense success to the companies with whom she has worked. As Founder and CEO of Platinum Pack, Elizabeth was responsible for all aspects of its success in bringing products from concept to completion and successful sell-through on the retailer’s shelf. She has been in the beauty industry for over 40 years.

Benjamin Perlstein, VP of Operations, has been a part of the health care and business development field for over 25 years. As a surgical technologist, he has experience as a clinical application specialist and materials manager.

Braden Traub, Director of Marketing and Customer Development, is an entrepreneur and business owner with 10 years of experience in the health and fitness industries. Traub also has skills and experience as a tax resolutionist and legal document preparer.

Safe Harbor for Forward-Looking Statements

Forward-looking statements are inherently subject to risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, including, without limitation, the following: the timing and nature of any capital raising transactions; the Company’s ability to offer products and services for use by customers in existing and new markets; the Company’s ability to deliver in a timely fashion and to its customers’ satisfaction the products purchased; the risk of competition; its ability to find, recruit and retain personnel with knowledge and experience in selling products and services in existing and new markets; its ability to manage growth; and general market, economic and business conditions. Additional factors that could cause actual results to differ materially from those anticipated by the Company’s forward-looking statements are under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in its Annual Report on Form 10-K for the fiscal year 2019 and its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, all filed with the Securities and Exchange Commission. Forward-looking statements are made as of the date hereof, and the Company expressly disclaim any obligation or undertaking to update forward-looking statements.

CannAssist International Corp. (OTCQB: CNSC), closed Monday’s trading session at $0.30, even for the day, on 12,380 volume. The average volume for the last 3 months is 776 and the stock's 52-week low/high is $0.200000002/$0.50.

Recent News

Knightscope, Inc.

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc..

Autonomous security robot (“ASR”) developer Knightscope is helping to revolutionize the operations of protective patrols used by private industry as well as the police forces employed by governmental institutions. The company’s indoor and outdoor-mobile ASR sentries have been contracted to help safeguard hospitals, university campuses, an NBA team and numerous Fortune 1000 companies. As evidence of the robots’ effectiveness and success, Knightscope’s investors number more than 17,000 now, among whom are law enforcement personnel and private security industry managers.

Knightscope, Inc., founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities and are on target to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics and artificial intelligence.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including ten Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country, despite the pandemic (note: robots are immune).

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire.

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology;
  • Operating for more than one million hours in the field and securing contracts across five time zones;
  • Navigating through the global pandemic without interruption by continuing to operate on a daily basis across the nation and supporting clients classified as essential services; and
  • Continuing its hiring processes despite the current societal and economic disruption.

Growth Capital

With more than 10,000 investors and over $40 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

The company is presently in the process of raising up to $50 million in growth capital as it prepares for a potential public listing. Knightscope has reserved ticker symbol ‘KSCP’ with Nasdaq.

Investors can buy shares exclusively through the company’s managing broker-dealer, StartEngine (http://nnw.fm/l9GLX) until July 20, 2020. Concurrent with this live offering and contingent upon various factors, including raising a sufficient amount of funds and meeting applicable listing standards, the company intends to begin preparation of an S-1 format Form 1-A and Nasdaq Capital Market application in anticipation of a possible public listing of the stock at the conclusion of the Regulation A+ offering.

Company Mission — The Greater Good

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting millions of law enforcement and security professionals across the country.

Crime has a negative economic impact in excess of $1 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was recently interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one to one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings — and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $4 to $11 per hour, compared with approximately $85 and $30 per hour for an armed off duty law enforcement officer and an unarmed security guard, respectively.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has four patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’.

The ASRs and all the related technologies were developed ground up by the Company and are Made in the USA.

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.


Recent News

chart

HempFusion Wellness Inc.

The QualityStocks Daily Newsletter would like to spotlight HempFusion Wellness Inc..

HempFusion Wellness, a leader in the health and wellness cannabidiol (“CBD”) industry, recently announced filing of its final prospectus with the securities regulatory authorities in each of Canada’s provinces, with exception to Québec. According to the update, the final prospectus was filed in connection with HempFusion’s previously-announced initial public offering of up to 7,000,000 of its common shares and up to 10,000,000 units of the company at a price of US$1.00 per offered share and per unit for gross proceeds of up to US$17,000,000. To view the full article, visit https://ibn.fm/7ueBG

HempFusion Wellness Inc. is a leader in the health and wellness CBD industry, providing innovative and diversified proprietary formulations utilizing the power of whole-food hemp nutrition.

Invested heavily in regulatory compliance, HempFusion aims to consistently meet and even exceed the high standards required by retailers and consumers – putting safety, quality and consistency first. In support of these efforts, the company is U.S. Hemp Authority Certified and is a current board member of the U.S. Hemp Roundtable, a coalition of leading companies committed to advancing safe hemp and CBD products.

HempFusion reported 1,750 shareholders and $18.3 million in cash as of June 30, 2020 – the second-largest cash position in its sector – with no debt. Looking ahead, the company is currently preparing to launch an IPO directly onto the Toronto Stock Exchange (“TSX”) senior board, where it has already reserved ticker symbol ‘CBD.U’. Learn More About HempFusion Upcoming IPO.

HempFusion is headquartered in Denver, Colorado.

HempFusion’s Proprietary Wellness Portfolio

The diverse product portfolio showcased by HempFusion includes 46 products that are currently on shelves. The company’s leading offerings include HempFusion-owned Biome Labs, HF Labs and Probulin. Due to the time and resources allocated to increasing the compliance of these proprietary products, HempFusion may have a competitive advantage and create additional retail opportunities that are not available for other CBD companies.

HempFusion’s Diversified Revenue Pipeline

HempFusion’s focus and investment into regulatory compliance has opened doors to major food and drug mass or big box retailers that are not available to other CBD companies. This strategic approach includes five distinct channels:

  • Natural Health Retailers
  • eCommerce
  • Big Box / Food and Drug Mass
  • Doctor Practitioner
  • Convenience

HempFusion’s Line of Products

HempFusion’s branded line of products is based on the company’s proprietary Whole Food Panoramic Full-Spectrum Hemp Complex. Each product is condition-specific, targeting needs such as sleep, energy and stress.

All of HempFusion’s products are made from DNA-verified, European Union registered, non-GMO, organic industrial hemp. The company’s offerings span multiple product categories, including:

  • Tinctures and capsules – These offerings make up the most popular product category in the $4 billion U.S. CBD market.
  • OTC topicals – HempFusion is one of the few CBD companies marketing FDA Drug Listed Topicals. The FDA compliance standards ensure that these products meet the standards set by larger national retailers.
  • Condition-specific OTC products – HempFusion has OTC products that are condition-specifically targeted, including:
    • OTC Pain Products – The global pain relief market for topicals is projected to reach $13.3 billion by 2025, with a CAGR from 2018 to 2025 of 7.4%.
    • OTC Eczema Products – The global dermatitis market is projected to reach $13.6 billion by 2026.
    • OTC Acne and Aging/Beauty Products – The global market for beauty and anti-aging products is currently estimated at $1.08 trillion.
    • OTC First Aid and Wound Healing Products – In 2019, the 10 top-selling first aid ointments in the United States generated over $650 million in sales.

Probulin Probiotics and Digestive Enzymes

Probulin Probiotics is a 100% wholly owned subsidiary of HempFusion Wellness Inc. and is currently one of the fastest growing probiotics brands in the United States, according to Spins syndicated data.

The Probulin product line addresses a wide range of consumer needs, including daily care, total care, women’s health and children’s products. The probiotics market represents a growing opportunity, as it is estimated to reach $7 billion globally by 2022.

Because of the diverse offerings of the Probulin line, it serves as HempFusion’s gateway to retailers who may not currently carry CBD products.

This ‘Trojan Horse Strategy’ is intended to allow the company to establish, develop and build relationships among these retailers. By achieving approved vendor status, the company may be able to facilitate faster onboarding times, enabling accelerated access to its CBD products in the future.

HF Labs and Biome Research – Doctor and Practitioner Product Lines

The HF Labs and Biome Research product lines are directed toward doctors and practitioners and cater to hospitals, compounding pharmacies and free-standing dispensaries. With an estimated target market of 28,000+ integrative medical doctors and 70,000+ licensed chiropractors in the United States, these offerings create a unique market opportunity as HempFusion continues to broaden its footprint in the CBD industry.

Research on CBD and Human Safety

HempFusion is one of 12 CBD companies selected to participate in ValidCare’s groundbreaking study regarding CBD and human safety, which is expected to be complete by the end of October 2020. The study is designed to address previous questions from the FDA regarding CBD products.

As part of this study, HempFusion and the other selected companies will be conducting human trials to determine if the daily use of full-spectrum hemp-derived CBD or CBD isolate impacts the human liver.

Management Team

Jason Mitchell, N.D., is the co-founder, Director and CEO of HempFusion. He has over 20 years of experience in the natural products industry and is a naturopathic doctor certified by the ANMCB. Mitchell received his doctorate from the Trinity College of Natural Health and is a member of the American Naturopathic Medical Association and the CNHP. He is an expert in supplemental formations and was responsible for successfully creating and launching over 300 industry-leading products during his 15-year tenure at Country Life Vitamins.

Ian DeQueiroz is the Chief of Brand Strategy & Partnerships and a Director for HempFusion. He is a serial entrepreneur with experience in early-stage cannabis and hemp companies. In 2010, he acquired his first cannabis CO2 extraction company in the United States. DeQueiroz has facilitated the licensing process for many companies in the United States, as well as one of Jamaica’s premier cannabis companies, Epican Medicinals Ltd.

Jon Visser is HempFusion’s Chief Revenue Officer. He has over 25 years of experience in all areas of sales and marketing, with a proven track record of consistently driving growth across all major channels. Visser was previously the Senior Vice President of Sales at Navajo Inc., a multi-national manufacturer/distributor of brands like Pennzoil Automotive Supplies, Piranha Eyewear and Navajo Inc., the largest distributor of trial- and travel-sized health and beauty products in the United States. Visser grew annual sales from $60 million to $128 million in less than three years while at Navajo Inc.

Bruce Valentine Jr. is the Chief Financial Officer of HempFusion. He has a proven track record working with high-growth companies and was named CFO of the Year in 2013 by the Northern Colorado Business Report. Valentine is the former CFO of Otter Products and has over 15 years of financial management experience.

Ola Lessard is the Chief Marketing Officer of HempFusion and is also the President of the U.S. Hemp Roundtable. She has experience in marketing creative and effective brand strategies. She is a former Vice President of Marketing at Barlean’s, an award-winning supplements provider based in Washington.

Nancy Angelini is the Director of the Doctor/Practitioner Channel. She has over 25 years as an active, licensed practitioner. Angelini travels the country as a lecturer and product manager. She is responsible for opening doors to some of the largest doctor/practitioner networks in the United States.

Daniel Brody is the Chief Corporate Officer of HempFusion. He is the co-founder and former Vice President of The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF). Brody has been instrumental in listing multiple world-class cannabis companies, including TGOD, Emblem Corp. and Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF). Before joining the cannabis industry, he spent seven years working at two leading Canadian brokerage firms.


Recent News

chart

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Net Element (NASDAQ: NETE) was featured today in a publication from Green Car Stocks, examining how the transport sector accounts for around 28.2% of total carbon emissions in North America. In a bid to cut down these emissions, reduce reliance on fossil fuels and improve air quality, several state governments have been considering banning the sale of new internal combustion engine vehicles in exchange for electric vehicles (“EVs”). Powered by clean, renewable energy, EVs produce zero emissions at the tailpipe, making them perfect for drivers keen on reducing their carbon footprint.

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Monday’s trading session at $12.35, off by 11.4695%, on 957,084 volume. The average volume for the last 3 months is 2,249,314 and the stock's 52-week low/high is $1.472/$20.0783996.

Recent News

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels (NYSE American: UUUU) (TSX: EFR), a leading producer of uranium in the United States, on Thursday announced that it has filed a prospectus supplement to its effective U.S. registration statement on Form S-3 in order to renew its "at-the-market" ("ATM") program. Under the program, the company may, at its discretion from time to time, sell up to an additional US$35.0 million of common shares, with sales only being made on the NYSE American at then-prevailing market prices, or any other existing trading market of the common shares in the United States. The prospectus supplement and the accompanying base shelf prospectus relating to this offering have been filed with the U.S. Securities and Exchange Commission ("SEC") and are available on the SEC's website at www.sec.gov. To view the full press release, visit http://ibn.fm/CVxpj

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Monday’s trading session at $3.94, off by 7.5117%, on 6,337,845 volume with 21 trades. The average volume for the last 3 months is 2,827,674 and the stock's 52-week low/high is $0.779999971/$4.81500005.

Recent News

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights to publicly traded companies through its software-as-a-service (“SaaS”) platform, Sequire, today announced that Lou Kerner will be appointed chief executive officer of its wholly owned subsidiary BIGtoken. SRAX previously announced its entry into a definitive agreement with Force Protection Video Equipment Corp (OTC: FPVD), pursuant to which SRAX will receive 88.9% of the issued and outstanding shares of FPVD in exchange for 100% of the shares of BIGtoken. To view the full press release, visit http://ibn.fm/FbcEV

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Monday’s trading session at $2.89, off by 7.074%, on 444,854 volume with 1 trade. The average volume for the last 3 months is 105,938 and the stock's 52-week low/high is $1.50999999/$3.79990005.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

The dawning of a new year is traditionally a time when people embrace the hope of new promise in defeating the disappointments of the past months, and the advent of 2021’s calendar is perhaps more so than ever as a growing number of vaccines against the worldwide COVID-19 pandemic begin to roll out to the public in tiered priority phases. Also just over the new year’s horizon is the launch of Phase 2 testing by neuro-oncology biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) as CNS advances an ambitious agenda for developing a drug candidate that has shown promise in the fight against glioblastoma, a deadly brain cancer that has no known cure or longevity-building treatment. Also today, the company was featured in a BioMedNewsBreaks from BioMedWire, examining how CNSP recently hosted a webinar to discuss the clinical design for its upcoming Phase 2 trial. The trial will study its lead drug candidate, Berubicin, for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable. Berubicin is an anthracycline that has demonstrated significant potential to effectively cross the blood-brain barrier and target central nervous system malignancies. To view the full article, visit: https://ibn.fm/jqKgo

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Monday’s trading session at $1.77, off by 0.561798%, on 732,529 volume with 5 trades. The average volume for the last 3 months is 1,096,763 and the stock's 52-week low/high is $1.25820004/$5.61999988.

Recent News

AzurRx BioPharma Inc. (NASDAQ: AZRX)

The QualityStocks Daily Newsletter would like to spotlight AzurRx BioPharma Inc. (NASDAQ: AZRX).

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal (“GI”) diseases, today announced its entry into an exclusive worldwide licensing agreement with First Wave Bio Inc. for the use of its patented and proprietary oral and rectal formulations of niclosamide for the treatment of immune checkpoint inhibitor-associated colitis (“ICI-AC”) and COVID-19 GI infections. To view the full press releases, visit http://ibn.fm/Dws3k and http://ibn.fm/PgjPr

AzurRx BioPharma Inc. (AZRX) is a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases using recombinant proteins.

The company’s lead drug candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients suffering from cystic fibrosis and chronic pancreatitis.

AzurRx has already completed two Phase 2 clinical trials for MS1819 and is currently pursuing approval through parallel monotherapy and combination therapy pathways.

The company was founded in 2014 and is headquartered in New York City, with scientific operations in Langlade, France, and clinical operations in Hayward, California.

MS1819 Clinical Trials

The two current ongoing clinical trials for MS1819 in cystic fibrosis (CF) are the Phase 2b Option 2 monotherapy trial and the Phase 2 combination therapy trial, using MS1819 together with porcine pancreatic enzyme replacement therapy (PERT), the current standard of care. Pending the Phase 2b trial outcome, the company intends to initiate a Phase 3 trial in cystic fibrosis.

  • Phase 2b CF Option 2 Trial – The study was initiated in Q3 2020, using MS1819 doses in enteric capsule form (2240mg and 4480mg). Topline data for the trial is anticipated in Q1 2021.
  • Phase 2 CF Combination Trial – The study was initiated in Q4 2019, using daily dose levels of PERT in combination with MS1819 dosages (700mg, 1120mg and 2240mg). Topline data is anticipated in Q2 2021.

These trials are currently addressing the treatment of EPI in patients with cystic fibrosis and chronic pancreatitis – an established global market with an estimated value in excess of $2 billion that has been growing at a CAGR greater than 20% over the past five years.

Results from AzurRx’s Phase 2b Option 2 trial of MS1819 in cystic fibrosis patients demonstrate that the non-porcine MS1819 lipase is well-tolerated by patients, with no significant safety signals observed at the 2240mg daily dose level.

“[W]e have evaluated four different enteric capsules and identified the best suitable formulation for MS1819 that provides gastroprotection of enzyme content and delayed release into the duodenum,” James Sapirstein, President & CEO of AzurRx, stated in a September 2020 news release (https://ibn.fm/27t4W). “Our clinical program continues to advance, and we are determined to develop MS1819 as a safer alternative to porcine pancreatic enzyme replacement therapy, significantly reducing the pill burden of cystic fibrosis patients.”

Financial Highlights

As of July 2020, AzurRx had raised gross cash capital of $22.1 million, including $15.2 million from Series B convertible preferred stock and warrants in July 2020 and $6.9 million from convertible promissory notes and warrants in December 2019 and January 2020. Notably, AzurRx solidified its financial position and created an effectively debt-free balance sheet by exchanging substantially all of its outstanding convertible notes into the Series B convertible preferred stock financing.

The company secured an additional $2.5 million in French Research Tax Credits, received in 2020, for the years 2017-2019 (https://ibn.fm/Qxk7O).

In a letter to shareholder, Sapirstein noted that ensuring the company maintains sufficient capital to support its business operations has been a key focus. He further stated that the company is in “a financially secure position” to complete its two Phase 2 MS1819 clinical trial programs and to begin preparations in 2021 for a pivotal Phase 3 study.

The company has no current plans to access additional financing, as it believes it has enough cash to fund existing operational and clinical objectives through Q3 2021.

Management Team

James Sapirstein is the President and CEO of AzurRx BioPharma. He was previously the CEO and a board member for ContraVir Pharmaceuticals Inc., which is now known as Hepion Pharmaceuticals Inc. (NASDAQ: HEPA). Mr. Sapirstein has almost 36 years of experience in the pharmaceutical industry, with expertise in drug development and commercialization. He currently serves on the Emerging Companies and Health Section boards of the BIO (Biotechnology Innovation Organization) and is Chairman Emeritus of BioNJ. He earned his Bachelor’s degree in Pharmacy from Rutgers University and has an MBA in management from Fairleigh Dickinson University.

Daniel Schneiderman is the Chief Financial Officer of AzurRx. He previously served as the CFO of Biophytis SA and its U.S. subsidiary, Biophytis, Inc., clinical-stage biotechnology companies focused on the development of pharmaceutical candidates for age-related diseases. He was appointed to the AzurRx position in January 2020, bringing to the team over 18 years of experience in capital markets and finance operations. Mr. Schneiderman holds a degree in economics from Tulane University.

James Pennington, M.D., is the Chief Medical Officer of AzurRx. Before joining the team, he was the Chief Medical Officer and Senior Clinical Fellow for 11 years at Anthera Pharmaceuticals. Before becoming a part of the biotech industry, Dr. Pennington was on the Medical Faculty of Harvard Medical School for 10 years. He received his medical degree from Oregon Health & Science University.

Martin Krusin is the Senior Vice President for Corporate Development at AzurRx. He has 20 years of experience in business development, strategic marketing, financing and operations in the health care, financial services and consulting sectors. Before joining AzurRx, he was the VP for Business Development at FluoroPharma Medical Inc. Mr. Krusin received his MBA from Columbia Business School in finance and marketing, an MPhil. in political economy from Oxford University and a BA in international relations from Swarthmore College.

Dinesh Srinivasan, Ph.D., is the Vice President for Translational Research at AzurRx. He has over 15 years of experience leading drug discovery and development in the pharmaceutical industry. He began his career as a post-doctorate fellow at Roche Palo Alto. Dr. Srinivasan received his MSc in Biotechnology from the University of Mumbai, India, and a Ph.D. in Pharmacology and Toxicology from the University of Arizona – Tucson.

Ted Stover is the Product Development Director at AzurRx. He joined the company in 2020 to oversee CMC and Project Management. Before joining AzurRx, he spent 20 years focused on manufacturing operations and analytical method development for all stages of pharmaceutical drug development. Mr. Stover earned his MBA from the University of Florida.

AzurRx BioPharma Inc. (AZRX), closed Monday’s trading session at $0.90, off by 7.2165%, on 6,751,604 volume with 59 trades. The average volume for the last 3 months is 348,222 and the stock's 52-week low/high is $0.370867997/$1.93830001.

Recent News

Pure Extracts Technologies Corp. (CSE: PULL)

The QualityStocks Daily Newsletter would like to spotlight Pure Extracts Technologies Corp. (CSE: PULL).

Pure Extracts Technologies Corp. (CSE: PULL) was featured today in a publication from PsychedelicNewsWire, examining how, in the past couple of years, biopharmaceutical firms focused on psychedelic medicines have increased in number. Two weeks ago, UK’s first psychedelic investment fund was launched. The fund is committed to psychedelic health care and hopes to invest in psychedelic medicines to treat conditions such as anxiety, addiction and depression. Also today, the company was featured in the 420 with CNW by CannabisNewsWire.

Pure Extracts Technologies Corp. (CSE: PULL), headquartered in Pemberton, British Columbia, is a plant-based extraction company with a new vertical in functional mushrooms. The firm is positioned to be the dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products.

The Company’s business model consists of three verticals: in-house brands; toll processing, offering contract cannabis and hemp processing to Canadian Licensed Producers and international partners to sell under their own brands; and white labelling, supplying products, including edibles and custom formulated oils, in consumer-ready packaging for companies licensed to sell cannabis oil extracts and for CPG brands seeking licensed cannabis manufacturing partners.

Market Position

The psychedelic and functional mushroom industries are among the fastest growing in North America. As the industry transitions from dry biomass to extracts, many companies are unprepared for this new opportunity. The global medicinal mushroom market is expected to grow by $13.88 billion annually by 2024.

When assessing investment strategy, market analysts suggest that psychedelics are more comparable to biotech than to cannabis. Unlike traditional biotech, however, psychedelics can claim years of human consumption. Because their efficacy and safety are already well understood, the hurdles for development are likely to be lower. As known molecules, psychedelics won’t spend as much time in discovery and pre-clinical development.

Current research is finding psychedelic benefits including anti-tumor, anti-viral, detoxification, immune function, and mental wellness. As such, psychedelic compounds are now being examined by leading medical research and academic institutions for treatment of depression, PTSD, anxiety, bi-polar disorder, obesity, narcolepsy, OCD, Alzheimer’s, ADHD and drug and alcohol dependence. In 2020, the FDA granted breakthrough therapy status to psychedelics for treatment-resistant depression, with approvals anticipated in 2021.

Pure Extracts is well positioned to partner with organizations planning to develop both functional and psychedelic products. A dealer’s license with Health Canada will enable buying, selling and producing of psychedelics in an EU-GMP-compliant environment. The Company’s 10,000 square foot facility is designed for EU-GMP certification, which allows for international sales. The Company has signed NDAs to explore joint development endeavors for Q4 2020 product launches, as well as an advisory agreement with Dr. Alexander MacGregor, founder of Transpharm Canada Inc. (“TCI”), the parent company of Toronto Institute of Pharmaceutical Technology, whose facility is a fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility and is a full-service clinical development business that provides clinical trial services to biotechnology companies.

Research on Psychedelics

Naturally occurring psychedelics, like psilocybin mushrooms, peyote and ayahuasca, have been used by humans for centuries. First seen as potentially medicinal in 1938 by a chemist at Sandoz Pharmaceuticals (now Novartis), the desired stimulant effect was unsuccessful and therefore the drug was shelved. Twenty years later, in 1958, Sandoz began selling lysergic acid diethylamide (LSD) to treat mental disorders. From 1950 to 1965, over a thousand scientific papers on these compounds were published. During the 1960s, however, psychedelics made their way out of the lab and onto the street. The war on drugs followed, and psychedelic research essentially ended.

Research continued slowly on the fringes. The Multidisciplinary Association for Psychedelic Studies was formed in 1986 with the goal of becoming a leading non-profit psychedelic pharmaceutical company. Still being researched, psychedelics’ primary and most common mechanism of action is agonism of serotonin receptors in the brain, which promotes serotonin production in order to regulate mood.

Growing societal awareness and acceptance of mental illness as a legitimate disease due, in part, to its increasingly prevalence have been a catalyst for a new search for innovative treatments. As such, interest in psychedelic medicines has been revived in recent years.

Extract Segment Leader with Cannabis

Canada’s cannabis industry is dominated by dried flower products. Extract products are estimated to represent only 13% of the market share. With no dominant brands in the cannabis sector, Pure Extracts is the development leader in this segment, which is estimated by Deloitte to be worth $2.7 billion annually. Pure Pulls, the company’s private label brand, is nationally recognized through compliant event sponsorship and ongoing product engagement.

Management Team

Pure Extracts is led by a team of dedicated professionals leveraging extensive industry knowledge.

Ben Nikolaevsky, the company’s CEO, has more than a decade of experience in corporate leadership roles across the natural products, agriculture and cannabis sectors. Nikolaevsky has served as CEO at Natura Naturals Inc. and Blue Goose Capital Corp., as well as market vice president at CIBC and chief credit officer & capital markets manager at IBM Global Financing Canada.

Doug Benville founded Pure Extracts and serves as the company’s COO. He is highly proficient in cannabis cultivation, system operations and oil extraction.

Alexander Logie, Pure Extracts’ vice president of business development, has over 30 years of experience in the financial services sector, having most recently served as interim CFO, COO and senior vice president of business development at Natura Naturals Inc., a licensed cannabis producer acquired at the start of 2019.

Andy Gauvin is vice president of sales for Pure Extracts. Gauvin is an accomplished senior sales leader with over 30 years of experience in the cannabis space. Gauvin also brings extensive knowledge of the complex federal and provincial regulatory environment to the Pure Extracts team.

Pure Extracts Technologies Corp. (CSE: PULL), closed Monday’s trading session at $0.62, off by 3.12%. The average volume for the last 3 months is 386,720 and the stock's 52-week low/high is $0.61/$0.65.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.